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The critical spread and dissemination of novel psychoactive substances (NPS), particularly 
among the most vulnerable youngsters, may pose a further concern about the psychotic 
trajectories related to the intake of new synthetic drugs. The psychopathological pattern 
of the “new psychoses” appears to be extremely different from the classical presentation. 
Therefore, clinicians need more data on these new synthetic psychoses and recommendations 
on how to manage them. The present mini-review aims at deepening both the clinical, 
psychopathological features of synthetic/chemical NPS-induced psychoses and their 
therapeutic strategies, according to the different NPS classes implicated, by underlining the 
main differences with the “classical” psychoses. A comprehensive review was conducted 
using the PubMed/Medline database by combining the search strategy of free-text terms and 
exploding a range of MESH headings relating to the topics of novel psychoactive substances 
and synthetic/chemical psychoses as follows: {(Novel Psychoactive Substances[Title/
Abstract]) AND Psychosis[Title/Abstract])} and for each NPS categories as well, focusing on 
synthetic cannabinoids and cathinones, without time and/or language restrictions. Finally, an 
overview of the main clinical and psychopathological features between classical versus NPS-
induced chemical/synthetic psychoses is provided for clinicians working with dual disorders 
and addiction psychiatry. Further insight is given here on therapeutic strategies and practical 
guidelines for managing patients affected with synthetic/chemical NPS-induced psychoses.
Keywords: psychosis, synthetic psychosis, chemical psychosis, novel psychoactive substances, NPS
INTRODUCTION
During the last decade, the “traditional” drug panorama has been gradually “reshaped” and integrated, 
even though not totally replaced, by the appearance of “new/novel psychoactive substances” (NPS) 
which are either newly created or existing substances which are now being used in “novel” modalities 
(1–3). The clinical, toxicological, and psychopathological effects of NPS have not been completely 
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investigated and discovered through modelling; hence, clinical 
and psychopathological/psychiatric concerns have arisen among 
clinicians/professionals working in dual diagnosis, drug addiction, 
and mental health area (1, 2, 4–6). The recent published report from 
the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) described more than 730 NPS notified to the agency 
by the end of 2018, with 55 new compounds reported for the first 
time in Europe only in 2018 (3). Of these, 51% were synthetic 
cannabinoids (SC), 24% synthetic cathinones/“bath salts,” 5% 
benzodiazepines, 2% synthetic opioids, and 18% other substances 
(i.e., tryptamines, phenethylamines, arylcyclohexylamines, 
psychostimulants, etc.) (3).
SC/“Spice drugs,” mainly marketed as nail polish remover, 
deodorizers, incense, and potpourri, labeled as “natural”/“legal” 
alternatives to cannabis, have been documented to be 
dramatically associated with extremely more severe adverse 
health effects compared to "classical" cannabis (1, 7). SC are 
mainly consumed by inhalation, typically smoked together with 
a dried herbal material onto which they are previously sprayed 
during the production phase with chemical additives, or by 
e-cigarettes, or sold in tablets, etc. (1, 7). SC are mainly sold and 
purchased in “smart-shops” and on online drug marketplaces 
(7). Among these adverse effects typically described are: cases 
of fatalities, cardiac dysrhythmias, seizures, liver toxicity, kidney 
failure, hypothermia, hypertension, myocardial infarction, 
cardiac arrest, acute tubular necrosis, interstitial nephritis, 
rhabdomyolysis, nausea, vomiting, cognitive deficits, memory 
loss, sedation, catatonia, agitation, irritability, sympathomimetic 
syndrome, subarachnoid hemorrhage, cerebrovascular 
accidents, hematuria, bloody noses, bleeding gums, internal 
hemorrhage, hemoptysis, panic attacks, anxiety, altered mental 
status, coma, and a peculiar “synthetic” psychosis, designated 
"Spiceophrenia" (1, 7). Moreover, animal studies demonstrated 
that the administration of SC to adolescent rodents or non-
human primates may determine the onset of a schizophrenia-
like phenotype in adulthood (8–11).
Being beta-keto-phenethylamines, synthetic cathinones (i.e., ethylone 
and methylone) are structurally similar to amphetamines [i.e., 3,4-methyl-
enedioxy-methamphetamine (MDMA), methamphetamine, etc.] 
and catecholamines, with subtle differences which modify their 
chemical, pharmacokinetic, and pharmacodynamic properties 
(1). Some cathinones are analogues of pyrovalerone, e.g., 
3,4-methylenedioxypyrovalerone (MDPV), naphyrone, 3, 
4-methylenedioxy-α-pyrrolidinobutiophenone (MDPBP),  and 
α-pyrrolidinovalerophenone (α-PVP) (12). Different synthetic 
cathinones may exert different effects and potency levels on the 
dopaminergic, noradrenergic, and serotoninergic pathways, even 
though all usually own sympathomimetic and/or amphetamine-
like effects (1). They are typically sold as pills, capsules, and 
powders, commonly insufflated (snorted/sniffed), orally consumed 
by “bombing” (swallowing the powder wrapped in a cigarette 
paper), mixed in a drink, or injected intravenously (13). Synthetic 
cathinones are generally known as “bath salts” in the USA and as 
“plant food” in Europe (1). Several motivations have been identified 
in their consumption and “appeal”/attractiveness among NPS and 
drug consumers, such as attaining feelings of euphoria/stimulation, 
increased energy, mood improvement, increasing empathy/
openness, reaching a more mental clarity, experiencing vivid 
hallucinations, and increasing libido. Synthetic cathinone users seem 
to frequently report hyperthermia, rhabdomyolysis, renal failure, 
seizures, as well cardiac, psychiatric, and other neurological signs, in 
addition to the onset of several levels of agitation, ranging from mild 
agitation to severe psychosis (14). Moreover, mood instability and 
paranoid ideation have been described among chronic users (15–
17). Furthermore, most synthetic cathinone consumers described 
tolerance, dependence, and withdrawal syndrome (1).
The class of synthetic hallucinogens/psychedelics includes all 
substances able to alter consciousness (i.e., synthetic lysergamides, 
tryptamines, and phenethylamines) by distorting time/motion/
color/sound perceptions of consumers and/or altering the 
perception of “self ” and/or stimulating some sensory/perceptual 
disturbances (1, 18, 19). Hallucinogens are usually consumed 
orally, occasionally through small blotter paper portions (i.e., 
“tabs”) held in the mouth to allow absorption through the oral 
mucosa. Moreover, it has been reported as route of administration 
by insufflation, smoking, rectal, and injection (intravenous 
and intramuscular) (1, 18, 19). The route of administration 
may influence the effects, their onset, and duration (1, 18, 19). 
Hypertension, tachycardia, hyperthermia, dizziness, sleeplessness, 
loss of appetite, xerostomia, sweating, impulsiveness, fast and 
labile emotional modifications (from fear, anxiety to euphoria), 
numbness, weakness, and tremors have been reported as frequent 
short-term effects. While long-term effects may comprise persistent 
psychosis (i.e., visual disturbances, disorganized thinking, and 
paranoia), mood fluctuations, and/or onset of a hallucinogen-
persisting perception disorder (HPPD) (1, 5, 19).
Synthetic/novel psychostimulants comprise several NPS 
classes, i.e., piperazines (compounds labeled as “legal” alternatives 
to ecstasy, mainly identified as cutting agents in some ecstasy 
pills) and “amphetamine-type stimulants” (ATS) (1, 3). ATS, 
e.g., PMA (4-methoxyamphetamine/“Dr. Death”), PMMA 
(4-methoxymeth-amphetamine), 4-MTA (4-methylthioampheta
mine/“flatliners”), DMA (2,5-dimethoxyamphetamine), aminorex 
derivatives (4,4″-DMAR); diclofensine, methiopropamine, 
etc., have been marketed as para-substituted methoxy drugs 
pharmacologically and clinically comparable to amphetamines 
(1, 3, 18). ATS are commonly supplied as tablets/crystals/powder, 
sometimes mixed with other substances (20). They are usually 
swallowed/smoked/snorted, and their common “street names” 
include “crystal meth” (aka “ice”)/“speed"/“crystal,” etc. (20). 
Obsessive delusions, paranoia, hallucinations, suicidal ideation, 
anxiety, insomnia, depression, and psychotic symptoms have 
been commonly reported following intake of ATS (20, 21).
Overall, NPS have been largely associated with several 
clinical and psychiatric symptomatology which may vary 
from the occurrence of an acute transient psychotic episode 
to more complex psychopathological patterns, depending on 
the substance implicated (and its pharmacological profile), 
the frequency, intensity and route of administration, and 
vulnerability and individual characteristics of NPS consumers 
(1, 4–6, 22, 24) (as shown in Table 1). The psychopathological 
pattern of NPS-induced “new/synthetic psychoses” appears 
to be extremely different from the classical presentation, 
by introducing a new interesting field of research from a 
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psychopathological and phenomenological point of view. 
More specifically, NPS mainly implicated in the onset of 
psychotic patterns are represented by SC, synthetic cathinones, 
psychostimulants, and some psychedelics/hallucinogenic NPS 
(1, 6, 19). However, as synthetic cannabinoids and cathinones 
are the most representative NPS groups, the present review 
mainly focused on these two categories in collecting, 
analyzing, and critically discussing data so far published about 
NPS-induced synthetic/chemical psychoses by underlining 
differences with “classical” psychosis.
TABLe 1 | Pharmacological and clinical features of the main NPS classes.
Type of NPS 
category
Description Neurotransmitter/pathways/receptors 
implicated
Clinical manifestations
Psychostimulants This category includes all compounds derived 
from psychostimulants (i.e., amphetamine, 
methamphetamine, MDMA, and cocaine). Some 
synthetic psychostimulants include the biochemical 
family of synthetic cathinones (see below) and 
novel stimulants, aminorex derivatives, ATS such as 
diclofensine, methiopropamine, 4,4′-DMAR, NBOMe-
series, 2C-series, etc.
Traditionally, psychostimulants primarily 
target monoaminergic systems, leading to 
increased extracellular levels of SER, DA, 
and/or NA.
Desired effects:
• Euphoria
• Social disinhibition
• Extroversion
• Increased energy
• Appetite suppressant
• "High"
Untoward effects:
• Serotoninergic syndrome
• Psychosis
• Paranoid ideation
• Impulsivity
• Mania
• Agitation
• Cardiovascular symptoms 
• Hyperthermia
Synthetic cathinones 
("bath salts")
This category includes analogues of naturally occurring 
cathinones such as Catha edulis (Khat). Synthetic 
cathinones are classified into: a) Substrates of DAT, 
SERT, and NAT (pharmacological profile similar to 
MDMA: i.e., butylone, ethylone, 4-MEC, etc.) b) 
Selective substrates of DAT (pharmacological profile 
similar to amphetamine and methamphetamine, i.e., 
methcathinone, flephedrone, etc.) c) Non-substrates of 
transporter inhibitors (i.e., MDPV, etc.) Some synthetic 
cathinones include mephedrone ("meow meow"), 
methedrone, methylone, 3-MMC, 2-MeOMC, 4-MeO-
a-PVP, 4-MeO-PBP, 4-MeO-PV9, 4-MPD, 4F-PV8, 
4F-PV9, 4F-PVP, a-PBT, a-PHP, a-PVT, dibutylone, 
DL-4662, Ethylone, MDPPP, MOPPP, NEB, Pentedrone, 
PV-8 (crystals), etc.
The mechanism by which synthetic 
cathinones exhibit an effect is similar 
to other stimulants through functionally 
changing monoamine transporters. They 
inhibit monoamine transporters, leading to 
increased extracellular levels of SER, DA, 
and NA. They exhibit a sympathomimetic 
activity.
Desired effects:
• Euphoria
• Hypervigilance
• Increased energy
• Openness
• Empathy
• Increased libido
• Appetite suppression
Untoward effects:
Excited delirium
Hallucinations
Agitation
Aggressiveness
Paranoid ideation
Exacerbation of mood disorders
Synthetic 
cannabinoids 
(synthetic 
cannabimimetics, 
synthetic 
cannabinoid receptor 
agonists, "Spice 
drugs," "legal 
cannabis alternative")
A wide range of brands of herbal products containing 
synthetic cannabinoids have been available on the 
market. They include, but are not limited to, Spice, Black 
Mamba, Annihilation, and Amsterdam Gold. New brands 
continue to emerge. Brand names are sometimes 
reminiscent of street names of strains of cannabis. 
Synthetic cannabinoids may be classified into seven 
major structural groups:
• naphthoyndoles (e.g. JWH-018, JWH-073, etc.);
• naphthylmethylindoles;
• naphthoylpyrroles;
• naphthylmethylindenes phenylacetylindoles (i.e. 
benzoylindoles, e.g. JWH-250);
• cyclohexylphenols (e.g. CP 47,497
• homologues of CP 47,497)\
• classical cannabinoids (e.g. HU-210).
They act on the endocannabinoid system, 
particularly on:
• CB1 (total agonism)
• CB2 (total agonism)
Desired effects:
• Relaxation
• Analgesia
• "High"
• Sedation
• Euphoria
• Anxiolysis
(Continued)
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TABLe 1 | Continued
Type of NPS 
category
Description Neurotransmitter/pathways/receptors 
implicated
Clinical manifestations
Untoward effects:
• Paranoid ideation
• Brief psychotic episode
• Persistent psychotic 
disorder/“Spiceophrenia”
• Cognitive impairment
• Anxiety/agitation
• Dyscontrol of impulses
• Dysphoria
• Manic symptoms
• Worsening of preexisting 
bipolar disorder and/
or psychosis and/or 
schizophrenia
• Seizures
• Tachycardia, hypertension, 
mydriasis, hyperglycemia, 
hypokalemia, dyspnea, 
tachypnea, nausea, vomiting
• Stroke, encephalopathy, renal 
failure
• Serotoninergic syndrome
Dissociatives The compounds included in this category produce 
dissociative effects similar to phencyclidine (PCP or 
“angel dust”), ketamine (“Special K” or “K” or “Ket”), 
methoxetamine etc. Some of NPS included in this 
category comprise 3-MeO-PCP, ethylketamine, 
3-HO-PCP, 4-MeO-PCP, Diphenidine, Methoxphenidine, 
etc.
Dissociative drugs act mainly as 
uncompetitive antagonists, through 
open channel blockade, of the glutamate 
ionotropic NMDA receptor. Dissociatives 
affect numerous other receptors (i.e., 
DA, opioid, 5-HT, adrenergic, nicotinic, 
muscarinic, and adenosine receptors) 
and ionic channels, leading to their 
occasional informal description of being 
neurochemically “dirty drugs.”
Desired effects:
• Dissociation/depersonalization 
(at high dosages)
• Analgesia
• “High” (at low dosages)
• Euphoria (at low dosages)
• “Out-of-body” or “near-death” 
experiences
• Weightlessness
Untoward effects:
• Headache
• Psychosis
• Reference ideation
• Hallucinations
• Flashbacks
• Nausea
• Dizziness
• Paranoia
• Anxiety
• Cognitive impairment
• Serotonergic syndrome 
(possible)
Hallucinogens 
(psychedelics/
psychotomimetics/
entheogens)
A category of substances developed as analogues of 
“classical” hallucinogens (i.e., LSD, psilocybin). They can 
be further divided into three subgroups:
• Phenethylamines (e.g., mescaline, Bromo-
DragonFLY, etc.)
• Tryptamines (e.g., psilocybin, 5-MeO-DALT, etc.)
• Lysergamines (e.g., LSD, AL-LAD, etc.) Novel 
tryptamines recently marketed include 5-MeO-DMT, 
5-MeO-DIPT, 4-HO-DALT, 5-MeO-AMT, DET, etc. 
Among the novel derivatives of “classical” psychedelic 
phenethylamines/MDMA-like drugs, we include the 
following: 2C-molecules (e.g., 2-CB/Nexus, 2C-I, 
2C-E, etc.), PMA/Dr Death, Bromodragonfly/B-
fly, 25C-NBOMe/N-bomb/Pandora, etc. Some 
hallucinogens also include herbs/plants such as Salvia 
divinorum, Mescaline, or other herb-related compounds 
previously used in traditional shamanic practices.
All three subgroups share a common 
mechanism on serotonergic system, 
represented by the agonism/partial 
agonism at the 5-HT2A receptor 
(activation), 5-HT1A, 5-HT2C. However, 
the different hallucinogenic/psychedelic 
drugs may differently interact with other 
neurotransmitters, i.e., NMDA receptors, 
σ-receptors, μ-opioid receptors, and 
muscarinic receptors, apart from causing 
serotonin and dopamine reuptake inhibition 
at their transporters.
Desired effects:
• Perceptual restructuralization
• Oceanic boundlessness
• Visual hallucinations
• Alterations in sensory 
perception
• Distortion in body image
• Depersonalization
• Entactogenic feelings
• Euphoria
(Continued)
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MATeRIAL AND MeTHODS
Search Sources and Strategies
A mini-review was conducted by analyzing and collecting clinical 
data (only human studies) on cases of NPS-induced psychosis, by 
using PubMed/Medline and focusing on synthetic cannabinoids 
and cathinones. We combined the search strategy of free-text 
terms and exploded MESH headings for the topics of “Novel 
Psychoactive Substances”  and “Synthetic/Chemical Psychoses” 
as follows: {(Novel Psychoactive Substances[Title/Abstract]) AND 
Psychosis[Title/Abstract])} and for each NPS category (synthetic 
cannabinoids and synthetic cathinones) as well, without time/
language restrictions. All studies published up to 30 June 2019 
were included. In addition, secondary searches were performed 
using the reference listing of all eligible as well as relevant articles 
and consultation with experts in the field and or manual searches.
Study Selection, Data extraction, and 
Management
We considered studies evaluating the relationships between 
NPS and synthetic psychosis. We examined all titles and 
abstracts and obtained full texts of potentially relevant papers. 
Working independently and in duplicate, two reviewers (LO 
and SC) read the papers and determined whether they met 
inclusion criteria. Duplicate publications were excluded. All 
experimental and observational study designs, including case 
reports, case series and surveys, were retrieved. Narrative and 
systematic reviews, letters to the editor, and book chapters 
were excluded, even though they were used for retrieving 
further secondary searches. To be included in the present 
review, studies were required to meet the following criteria: 
a) empirical and peer-reviewed study; b) at least an abstract 
with estimates and/or full results published in English; 
c) human studies; and d) provide data on synthetic psychosis 
induced by NPS. LO and SC independently extracted the 
data on participant characteristics, intervention details, 
and outcome measures. Disagreements were resolved by 
discussion and consensus with a third member of the team 
(GDP). Data were collected using an ad hoc developed data 
extraction spreadsheet.
Characteristics of Included Studies
The set of keywords initially generated 402 results. A total of 123 
papers were excluded because of duplication; seven papers were 
excluded through lack of an english abstract. Of the remaining 
272 studies, 145 studies were excluded because they did not meet 
the inclusion criteria or because they were animal studies. Of the 
remaining 127 papers, 37 papers were excluded because they were 
reviews, letters to editors, or meta-analyses, while seven papers 
were not included here due to the lack of an available full text or 
an abstract useful for collecting relevant data. Finally, a total of 83 
papers were included and accounted for in our analysis. Table 2 
clearly explains the main characteristics (study design, sample 
size, main outcomes, and findings) of all studies retrieved.
ReSULTS
Data on NPS-Induced Psychosis in 
General
A cross-sectional survey carried out as a retrospective review of 
electronic discharge letters of all patients discharged from general 
adult psychiatric wards in the Royal Edinburgh Hospital recruited 
483 admissions, 86 of which had NPS involvement reported. 
Among NPS users, the diagnosis of drug-induced psychosis was 
significantly higher (p < .001, OR = 18.7) compared to non-NPS 
users (25). The European Drug Emergencies Network (Euro-
DEN) collected data on presentations to emergency department 
(ED) with acute recreational drug and/or NPS intoxication in 16 
sentinel centers in 10 European countries, reporting psychosis 
TABLe 1 | Continued
Type of NPS 
category
Description Neurotransmitter/pathways/receptors 
implicated
Clinical manifestations
Untoward effects:
• Anxiety
• Agitation
• Psychosis
• Hallucinations
• Serotonergic syndrome 
(possible)
Sedatives/analgesics This category includes the synthetic/derivatives opioids 
(i.e., AH-7921, IC-26, MT-45, nortilidine, W15, W18, 
U-47700, lefetamine, etc.) and designer/synthetic 
benzodiazepines (i.e., etizolam, flubromazepam, 
flubromazolam, phenazepam, pyrazolam).
They may act on opioid system and/or 
GABA system.
Desired effects:
• Analgesia
• Sedation
• Emotional
Untoward effects:
• Lack of consciousness
• Somnolence/sedation
• Respiratory depression
• Coma and death
ATS, amphetamine-type stimulants; SER, serotonin; DA, dopamine; NA, noradrenalin; SERT, serotoninergic transporter; DAT, dopamine transporter; NAT, noradrenergic transporter; 
NMDA, N-methyl-D-aspartate.
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TABLe 2 | Summary of included studies.
Reference Study design 
(country)
Sample 
features (size, 
age, ethnicity, 
sex)
Psychiatric history NPS involved Symptomatology Previous 
substance use 
history
Treatment [drug 
name, dosage, 
duration (if 
available)]
Studies on NPS-induced psychosis in general (unspecified or multiple NPS involved)
Stanley et al. 
(25)
Cross-sectional 
survey (UK)
86/388, 36.1 ± 
9.4; NA, 60 M 
and 26 F
Personal psychiatric 
history of schizophrenia, 
schizoaffective disorder, 
and personality disorders
NPS unspecified Psychosis NPS users present 
significantly higher 
levels of cannabis, 
alcohol, and 
substitute opiate use
General adult 
psychiatric ward 
(NA, NA, NA)
Vallersnes et al. 
(26)
Retrospective cohort 
study—European 
Drug Emergencies 
Network (Euro-DEN, 
several countries)
5,529, 24-38, 
NA, 79.3% M
NA MDPV (27.3%), 
tryptamines (57.1%), 
methylphenidate (23.1%), 
SC (15.4%), mephedrone 
(5.7%), methedrone 
(3.3%)
Psychosis, significantly associated 
with agitation (63.2%; p < .001); 
hallucinations (43.7%, p < .001) and 
anxiety (37.1%, p < .001)
NA ED (NA, NA, NA)
Liakoni et al. (27) Retrospective cohort 
study (Switzerland)
157,328, 16–74, 
NA, 68% M
NA 2 cases with NPS (2C-P 
and methylone)
Psychosis NA ED (NA, NA, NA)
Studies on synthetic cannabinoid-induced psychosis
Every-Palmer 
(28)
Case report (New 
Zealand)
NA, NA, NA, NA Personal psychiatric 
history of psychotic 
disorder (n = 5)
“Aroma” blend, 
containing CP-47,497 
and/or JWH-018 (SC)
Mental states deteriorated 
significantly after use including 
sudden re-emergence of florid 
psychosis, predominantly agitation, 
disorganization, and delusional 
beliefs (n = 5)
NA NA
Müller et al. (29) Case report 
(Germany)
1, 25, NA, M Personal psychiatric 
history of cannabis-
induced recurrent 
psychotic episodes 
associated with a strong 
family history of paranoid 
schizophrenia
Spice (SC) Anxiety, psychotic symptoms with 
feelings of manipulation, worsening of 
symptomatology (imperative voices 
and paranoid hallucinations)
Cannabis NA
Rodgman and 
Kinzie (30)
Case report (USA) 3, NA, NA, NA NA "Mojo" (SC) Acute psychosis NA Beta-blockers (NA), 
low dose of BDZs 
(NA)
Sobolevsky 
et al. (31)
Case report (Russia) 3, 22 ± 1, NA, 2 
M and 1 F
NA Tropical Synergy (SC) 
containing JWH-018, CP 
49,497
Anxiety, tachycardia, paranoia, 
hallucinations, short-term memory, 
and sense of time impaired
NA NA
Vearrier and 
Osterhoudt (32)
Case report (USA) 1, 17, NA, F None JWH-018 (SC) Violent and “crazy” visual 
hallucinations, lower extremities 
numbness, muscle twitches, elevated 
pulse, dilated pupils, anxiety
Occasionally abuse 
alcohol and cannabis
ED, LOR (2 mg ev, 
once)
Benford and 
Caplan (33)
Case report (USA) 1, 20, NA, M None Spice (SC) Severe anxiety and paranoia, auditory 
and visual hallucinations, halted 
speech
Cannabis ED
(Continued)
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TABLe 2 | Continued
Reference Study design 
(country)
Sample 
features (size, 
age, ethnicity, 
sex)
Psychiatric history NPS involved Symptomatology Previous 
substance use 
history
Treatment [drug 
name, dosage, 
duration (if 
available)]
Castellanos 
et al. (34)
Case series (USA) 11, 15–19, NA, 
10 M and 1 F
Personal psychiatric history 
of ADHD (n = 3); ADHD + 
learning disorder + MDD 
(n = 1); none (n = 7)
SC Euphoria, irritability, anxiety, 
numbness, memory impairment, 
auditory and visual hallucinations, 
paranoia, palpitations, muscle 
tremors, weakness, blackouts, 
restlessness, stimulation
Cannabis and 
alcohol use (n = 10)
NA
Every-Palmer 
(35)
Case series (New 
Zealand)
9/15, 18–65, 
NA, M
Personal psychiatric 
history of schizophrenia 
(n = 10), schizoaffective 
disorder (n = 4), bipolar 
disorder with psychotic 
features (n = 1)
JWH-018 (SC) Excited psychotic symptoms, relapse 
of psychosis (agitation, delusions 
and disorganization after SC intake), 
anxiety, paranoia
Cannabis NA
Forrester et al. 
(36)
Retrospective cohort 
study (USA)—Texas 
Poison Center 
Network (2010)
464, 12–67, NA, 
343 M and 118 F
NA SC Agitation (18.5%), hallucinations 
(10.8%), drowsiness (18.5%), 
vomiting, nausea, tachycardia
Alcohol, cocaine, 
acetaminophen, 
hydrocodone, 
chlorpeniramin, 
dextromethorphan, 
carisoprodol
Hospitalization, 
ev fluids, 
BDZs, oxygen, 
antiemetics, AC 
(NA)
Hurst et al. (37) Case series (USA) 10, 21–25, NA, M None SC Auditory hallucinations, paranoid 
delusions, blocked thoughts, 
disorganized speech and behavior, 
suicidal ideation, alogia, ideation, 
insomnia, flatted affect, psychomotor 
retardation and/or agitation, anxiety
Concurrent cannabis 
or alcohol use (n = 8)
Hospitalizations 
(n = 7), not specified 
AP (n = 10) (NA)
Johnson et al. 
(2011)
Case report (USA) 1, 23, Caucasian, 
M
None Spice (SC) smoked 
96 and 48 h before 
admission
Paranoia, disorganized thoughts, 
nonsensical speech, delusion
Earlier cannabis use 
over 3 years ago
Spontaneous 
remission after 24 h
Locatelli et al. 
(39)
Retrospective cohort 
study (Italy)—Pavia 
Poison Centre and 
National Early Warning 
System for Drugs
17, 14–55, 
Caucasian, NA
NA “Spice” (n = 1), “N-Joy” 
(n = 6), “Forest Green” 
(n = 3), “Jungle Mystic 
Incense” (n = 5), JWH 
(n = 2), all SC
Agitation, confusion, hallucinations, 
dyspnea, coma, seizure, mydriasis, 
xerostomia, vertical nystagmus, 
psychomotor agitation, vomiting
NA BDZs (NA), 
symptomatic 
treatment
McCain et al. 
(40)
Retrospective cohort 
study (USA)—Arkansas 
Poison and Drug 
Information Center 
(March–August 2010)
6/9, NA, NA, NA NA SC Agitation/irritability (50%), 
hallucinations (33.3%), confusion 
(66.7%), nausea (33.3%), mydriasis 
(33.3%), pallor (33.3%), tachycardia 
(100%), hypokalemia (100%)
NA BDZs (NA), 
supportive infusive 
therapy
Simmons et al. 
(41)
Case report (USA) a) 1, 25, NA, M b) 
1, 21, NA, M c) 1, 
19, NA, M
None "Spice” (SC) containing 
JWH-018, JWH-073
a) Seizure, tachycardia, acidosis, 
unresponsiveness to verbal 
stimuli, "eye-crossed and flailing 
arms", mydriasis b) Hypertension, 
unresponsiveness, agitation, c) 
Delusions, paranoia, short-term 
memory impairment, bizarre behavior, 
muscle spasm, depressed breathing
None BDZs (LOR, 
4 mg, NA), APs 
(HALO, 5 mg, 
NA), supportive 
infusive therapy and 
observation
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Young et al. (42) Case report (USA) 1, 17, NA, M None “K9” smoking (SC) Hallucinations, dizziness, tachycardia, 
chest pressure that lasted for 3 days, 
difficulty breathing, lightheadedness
Occasional alcohol 
use
NA
McGuiness and 
Newell (43)
Case report (USA) 1, 18, NA, F NA SC Paranoia, chest pain, 
hyperventilation, nausea, panic 
attack, ideas of reference
NA NA
Tung et al. (44) Case report (Hong 
Kong)
1, 36, Chinese, M Family psychiatric history 
of SMI (unspecified) and 
SUD
“K2” (SC) daily for 
4 weeks before 
admission
Agitation, profuse seating, 
tachycardia, delusion, elevated 
blood pressure, irritability, insomnia, 
restlessness, accelerated speech
Previous abuse 
history of multiple 
psychoactive 
substances (codeine, 
heroin, and other 
unspecified)
Hospitalization; 
spontaneous 
remission
Van der Veer 
and Friday (45)
Case report (USA) 3, 20–30, NA, M Personal psychiatric 
history: none (n = 1), PTSD 
(n = 1), amphetamine-
induced brief psychotic 
episodes (n = 1)
“Spice” (SC) 3–4 weeks 
before admission
Persistent psychosis after SC intake, 
disorganized speech, poverty of 
thought, loosening of associations, 
paranoia, delusion, aggressiveness, 
inappropriate affect, suicidality, 
"Capgras delusions"
Previous cannabis 
use
Hospitalization; 
HALO (n = 2, NA, 
NA), RIS (n = 1, 
NA, NA)
Bebarta et al. 
(46)
Case report (USA) 3, 19–23, NA, 2 
M and 1 F
NA “Spice” (n = 1) and 
“Space” (n = 2), all 
containing SC
Paranoia, hallucinations, agitation, 
tachycardia, hyperglycemia, mild 
drowsiness, short-term memory 
impairment, hyperglycemia, anxiety, 
agitation, breathing difficulty, 
hyperventilation, tachycardia, injected 
sclera
None ED observation; 
LOR (2 mg, NA)
Cohen et al. (47) Case report (USA) 3, 16–18, NA, 2 
M and 1 F
NA SC Catatonia, tachycardia, vertical 
nystagmus, agitation, aggression 
restlessness, tachycardia, 
hyperventilation, disorientation, 
slowed speech
NA NA
Hoyte et al. (48) Retrospective Cohort 
study (USA)—National 
Poison Data System 
(January–October 
2010)
1898, 20 
(median), NA, 
74.3% M
NA “K2” and “Spice Gold”, all 
containing SC
Hallucinations, delusions (9.4%) NA BDZs (n = 16%, 
NA, NA)
Oluwabusi 
et al. (49)
Case report (USA) 2, 16–17, 
Hispanic, M
None “K2” and “Spice”, all 
containing SC
New-onset psychosis, insomnia, 
hyperactivity, anxiety, paranoid 
and grandiose delusions, musical 
auditory hallucinations, colorful visual 
hallucinations, low mood, agitation, 
irritability, pressure of speech, flight 
of ideas, disorganized behavior, 
thought broadcasting, somatic 
preoccupation, mild cognitive 
impairment
NA Hospitalization, ARI 
(n = 1, 20 mg daily, 
NA), OLA (n = 1, 15 
mg daily, NA)
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Peglow et al. 
(50)
Case report (USA) 1, 59, Latin, M PTSD Smoking two joints of 
“Spice” (SC) daily for the 
previous 3 weeks before 
admission
New-onset psychosis, visual 
hallucinations, disorganized and 
bizarre behavior, consciousness 
disorder, flashbacks of trauma
Alcohol, heroin, 
cocaine, cannabis 
discontinued 3 years 
before
Hospitalization, 
BZDs (NA, NA, 
NA), gabapentin 
(400 mg QID), 
hydroxyzine (25 mg 
TID), ARI (10 mg 
qD), benztropine 
(1 mg BID), BUP 
(150 mg BID)
Vandrey et al. 
(51)
Internet-based survey 
(13 different countries)
391, 26 ± 9, 
90% Caucasian, 
83% M
NA “Spice” (SC) Hallucinations (28%) Alcohol (92%) 
Cannabis (84%)
NA
Barratt et al. (52) Online questionnaire 
using purposive 
sampling strategy 
(Australia)
316, 23–34, NA, 
77% M
NA SC Paranoia (18%) Psychosis (4%) Cannabis (96%) NA
Berry-Cabán 
etal. (53)
Case report (USA) 1, 20, Hispanic, 
M
None “Spice” (SC) New-onset psychosis, 
uncommunicative, unable to follow 
commands, combative
Alcohol, "plant food" Hospitalization, 
LOR (2 mg, three 
administrations 
during 
hospitalization), 
HALO (5 mg once), 
RIS (1 mg daily, NA)
Chan et al. (54) Case-report (UK) 1, 21, NA, M None 6-APB (SC), metabolites 
of both THC and JWH-
122 (SC)
Delusions (“trying to read his mind”, 
“looking at him in a funny way”), 
agitation, suicidal and homicidal 
tendencies, paranoia, low mood
Cannabis Hospitalization, 
diazepam 
(4–10 mg, NA)
Hermanns-
Clausen et al. 
(55)
Retrospective cohort 
study (Germany)—
Database of the 
Poisons Information 
Center Frelburg 
(2008–2011)
29, 14–30, NA, 
25 M and 4 F
NA SC Mild visual or auditory 
hallucinations, tachycardia, 
drowsiness, paresthesia, abdominal 
pain, mild hypoglycemia, mild 
electrolyte imbalance, short-term 
hypothermia, delirium, agitation, 
confusion, rhabdomyolysis, etc.
NA Supportive 
care, potassium 
supplementation, 
BDZs (NA)
Papanti et al. (7) Case report (Italy) 1, 18, Caucasian, 
M
None “Bonzai” herbal blend 
(SC)
Anxiety, insomnia, palpitations, ideas 
of reference, somatic and visual 
hallucinations, autoscopy, agitation, 
behavioral dyscontrol
None Hospitalization with 
diazepam 5 mg ev, 
then, bromazepam 
3 mg daily and 
OLA 5 mg daily for 
4 weeks
Glue et al. (56) Case series (New 
Zealand)
17, 26.1 ± 10, 
NA, 10 M and 7 F
Personal psychiatric 
history of recurrences 
of preexisting affective 
disorders (n = 9/17)
“K2” (SC) Paranoia, thought disorder, 
disorganized behavior, anxiety, 
depression, suicidal ideation
NA Hospitalization, 
ADs (NA, NA), APs 
(NA, NA)
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Leibu et al. (57) Case report (USA) 1, 36, African-
American, M
Personal psychiatric 
history of schizophrenia 
and cannabis 
dependence
“K2” (SC) 3 times 
smoked weeks before 
admission
Worsening paranoia, illogical speech 
and auditory hallucinations
Previous cannabis 
use
Hospitalization, 
ECT, CLO (225 mg 
BID, NA)
Bozkurt et al. 
(58)
Survey on 
sociodemographic 
and clinical data 
(Turkey)
158, 26.1 ± 7.1, 
NA, 94.9% M
Personal psychiatric 
history of comorbid 
psychiatric disorders (7%)
“Bonzai” (SC) in 70.3% 
“Jamaika” (SC) in 21.5%
Hallucinations (40.4%), delusions 
(16%)
Cannabis NA
Celofiga et al. 
(59)
Case report (Slovenia) 4, 21–35, NA, M Personal psychiatric 
history of schizophrenia
AM-2201 (SC) Delusions, hallucinations (n = 2), 
psychosis relapse
None None (n = 1), 
increased BDZs 
(n = 3)
Haro et al. (60) Case report (Spain) 1, 18, NA, F NA SC for at least 6 months New-onset psychosis, violent 
behavior, talking to self, visual 
hallucinations
Cannabis ARI (15 mg daily, 
2 months), LOR 
(NA, NA), Biperiden 
(NA, NA)
Meijer et al. (61) Case report (USA) 1, 26, NA, M Personal psychiatric 
history of ADHD stable 
with lisdexamfetamine
“Black Diamond” (SC) New-onset psychosis, paranoid 
delusions
NA Amputation
Smith and 
Roberts (62)
Case report (USA) 1, 17, NA, M None “K2” daily for 2 months 
before admission
Auditory and visual hallucinations, 
catatonia, disorganized thought 
process, new-onset psychosis
NA Hospitalization, LOR 
(2 mg daily, NA), 
OLA (NA, NA), ECT 
(6 sessions, NA)
Durand et al. 
(63)
Case report (USA) 1, 23, NA, M Family psychiatric history 
of schizophrenia
“Mr. Nice Guy” (SC) 
sporadically for 6 months
New-onset psychosis, persecutory 
delusions
Cannabis Hospitalization; 
HALO (10 mg 
TID, NA), VA 
(500–1,000 mg, 
NA), LOR (2 mg 
TID, NA)
Schwartz et al. 
(64)
Case series (USA) 7, 16–30, NA, 
3 M and 4 F
None “Crazy Clown” (SC) Delirium, new-onset psychosis, 
aggressive behaviors
1 subject with 
cocaine use
ICU, intubation (n = 3), 
no treatment (n = 3), 
normal saline (n = 1)
Ustundag et al. 
(65)
Case report (Turkey) 1, 18, NA, M None SC for 6 months Talking to self and laughing, new-
onset psychosis, delusions, manic 
symptoms
Volatile substances OLA (10–20 mg 
daily, NA), VA (500–
1,500 mg daily, NA), 
QUE (200–400 mg 
daily, NA)
Sönmez and 
Köşger (66)
Case report (Turkey) 1, 31, NA, M None “Bonsai” (SC) 3 times a 
week for >6 months
Anger, insomnia, delusions, new-
onset psychosis
None Hospitalization; OLA 
(NA)
Rahmani et al. 
(67)
Case report (USA) a) 1, 17, 
Caucasian, M b) 
1, 17, Caucasian, 
M
a) Strong family 
psychiatric history 
b) Strong family 
psychiatry history
“Spice” (SC) a) Delusions, visual hallucinations, 
new-onset psychosis b) Paranoia, 
disorganized thought and behavior, 
new-onset psychosis
a) Cannabis, 
LSD, psilocybin, 
mushrooms, bath 
salts, oxycodone 
b) Cannabis, 
LSD, ecstasy, 
benzodiazepines
a) Hospitalization, 
CLO (NA), 
metoprolol (NA) 
b) Hospitalization, 
CLO (NA)
(Continued)
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Tyndall et al. (68) Retrospective cohort 
study (USA)
35, 14–58, NA, 
88.6% M
NA SC Hallucinations (6%) NA Hospitalization 
(28%)
Altintas et al. 
(69)
Cross-sectional study 
(Turkey)
50/81, 25.9 ± 
5.5, NA, M
Strong family psychiatric 
history and personal 
psychiatric history of 
substance use disorder 
(36%)
SC Paranoia, disorganized behavior, 
suicide thoughts, anxiety, visual and 
auditory hallucinations
Cannabis NA
Khan et al. (70) Case report (USA) a) 1, 21, African-
American, M b) 1, 
17, Caucasian, M
a) Personal psychiatric 
history of untreated 
childhood ADHD b) None
a) Continuous heavy use 
of "Kush" for the previous 
18 months b) 2-week 
"Spice" binge
Catatonia, incongruent affect and 
paraphasic errors, flat affect, blank 
stare, echolalia, muscle rigidity, 
bradykinesias, psychosis, euphoria, 
grandiosity, paranoia, decreased 
sleep, disorganization
a) Occasional 
previous cannabis 
use b) Periodic 
cannabis smoking for 
1 year prior
a) Hospitalization; 
ARI (25 mg daily, NA) 
b) Hospitalization; VA 
(100 mg qHS, NA), 
LOR (2 mg BID, NA), 
OLA (NA, NA)
Hermanns-
Clausen et al. 
(71)
Retrospective cohort 
study (Germany)—
Poisons Information 
Center (2011–2014) 
and Institute of 
Forensic Medicine of 
the University Medical 
Center Freiburg
22/46, 12–25, 
NA, 18 M and 4 F
NA SC Visual hallucinations (23%), 
perceptual disturbance (9.1%), 
retrograde amnesia (4.5%), 
tachycardia (82%), nausea (78%), 
somnolence (55%), mydriasis (45%), 
restlessness (13.6%), agitation 
(13.6%),
Alcohol (n = 1) BDZs (n = 2, 
NA), metoprolol 
(n = 3, NA), 
metoclopramide 
(n = 2, NA), 
ondansetron 
(n = 2, NA), 
diphenhydramine 
(n = 2, NA), 
lamotrigine (n = 
1, NA)
Bassir Nia et al. 
(72)
Retrospective cohort 
study (USA)
82/676, NA, NA, 
NA
NA SC ± cannabis Subject with SC use only were 
significantly associated with more 
psychotic symptoms (OR = 4.44), 
more psychotic disorder diagnosis 
(OR = 6.74), and greater agitation 
(OR = 4.39) and aggression (OR = 
3.10), followed by subjects with SC 
and concomitant cannabis use (OR 
= 3.61, OR = 4.78, and OR = 2.51, 
respectively)
NA APs, MS, AD (NA, 
NA)
Roberto et al. 
(73)
Case report (USA) 1, 18, African 
American, M
None "K2" and "Spice" daily for 
3–4 weeks
Insomnia, paranoid ideation, 
agitation, elated mood, beliefs that 
others were inserting thoughts into 
his head ("thought insertion" and 
"thought broadcasting"), pacing, 
bizarre delusional thoughts with 
thought derailment, disorganized 
behavior, decreased short-term 
memory
Alcohol and cannabis Hospitalization; RIS 
(5 mg daily, NA), 
LOR (2 mg, NA)
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Samaan et al. 
(74)
Case report (USA) 1, 18, Hispanic, 
M
None SC Acute-onset auditory hallucinations, 
paranoid delusions, panic attacks, 
palpation, shortness of breath, 
diaphoresis, chest tightness, 
hand numbness, impulsivity, 
aggressiveness, agitation, suicidal 
thoughts
Cannabis NA
Ozer et al. (75) Case report (Turkey) 1, 17, NA, M None Inhaled "Bonsai" (SC) for 
10 days before admission
Capgras syndrome, persecutory 
delusions and auditory hallucinations
NA Hospitalization; 
OLA (10 mg daily, 3 
months)
Shalit et al. (76) Retrospective cohort 
study (Israel)
60, 30.46 ± 7.83, 
NA, 86% M
NA SC Higher PANSS score in SC users 
vs. cannabis users No differences in 
major psychiatric diagnoses between 
SC vs. cannabis users
Cannabis (73.3%) Hospitalization
Waugh et al. (77) Retrospective cohort 
study (UK)—National 
Poisons Information 
Service telephone 
enquiry records 
(2007–2014)
510, 12–78, NA, 
80.8% M
NA "Black Mamba" (SC) in 
20.3% "Pandora's Box" 
(SC) in 15% "Clockwork 
Orange" (SC) in 6.2%
Hallucinations (4.6%), paranoia 
(1.2%)
9% previous use of 
other substances
NA
Zorlu et al. (78) Case–control (Turkey) 22 SC users vs. 
18 HC, 26.5 ± 
5.2, NA, NA
NA SC Long-term use of SC associated 
with white matter abnormalities 
and disturbed brain connectivity 
associated with an increased 
vulnerability to psychosis
NA NA
Babi et al. (79) Case report (USA) 1, 40, NA, M None SC Acute psychosis, new-onset 
refractory status epilepticus
None LOR ev (NA, NA), 
VA (NA, NA), 
levetiracetam (NA, 
NA), lacosamide 
(NA, NA)
Manseau et al. 
(80)
Retrospective cohort 
study (USA)
110, 33 (median), 
non-white (90%), 
95.5% M
Personal psychiatric 
history of primary 
psychotic disorder 
diagnosis (40%)
SC Acute psychotic symptoms (70%), 
agitation
Alcohol (39.1%), 
cannabis (35.5%), 
cocaine (24.5%)
Inpatient admission 
(34.5%), unspecified 
APs
Monte et al. (81) Retrospective cohort 
study (USA)—Toxic 
Registry (2010–2015)
353, 25 (median), 
NA, 84% M
NA SC Delirium and toxic psychosis (41.4%), 
hallucinations (7.1%)
3.4% previous 
cannabis use whilst 
5.7% previous use of 
other substances
BDZs (37%) 
and unspecified 
APs (10%) 
most frequently 
prescribed
Kassai et al. (82) Qualitative research 
(Hungary)
6, 20–27, NA, M NA SC Paranoia, difficulty socializing, 
increased egoism, self-neglect, 
switch off brain, inability to sleep, 
feeling under control, sweating
NA NA
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Van Hout and 
Hearne (83)
Online survey (UK) 6, NA, NA, 3 M 
and 3 F
NA SC Agitation, restlessness, fear, paranoia, 
aggression, severe dissociation, chest 
pain, aches and pains, palpitations, 
nausea, sweating, vomiting
NA NA
Welter et al. (84) Prospective pilot 
study (Germany)
24/332, 23.52 ± 
5.29, NA, 71.4% 
M
Personal psychiatric 
history of schizophrenia, 
schizoaffective disorder 
and schizophrenic 
disorder (71.4%)
SC ± cannabis SC use was 2 times higher among 
psychotic patients vs. non-psychotic 
patients (p = .033). Delusion 
of persecution, hallucinations, 
blunted affect, motor retardation, 
disorganization or worsening of 
preexistent psychotic symptoms
Cannabis NA
Bonaccorso 
et al. (85)
Case series (UK) a) 1, 28, 
Caucasian, 
M b) 1, 32, 
Caucasian, F 
c) 1, 20, Black-
Caribbean, M 
d) 1, 39, Asian 
British, M
a) Personal psychiatric 
history of paranoid 
schizophrenia b) Personal 
psychiatric history of 
schizoaffective disorder, 
poly-substance misuse 
(cocaine and heroin) 
c) Personal psychiatric 
history of first psychotic 
episode post poly-
substance misuse d) 
Personal psychiatric 
history of bipolar disorder
SC Intense exacerbations of positive 
symptoms, psychomotor agitation, 
sexual disinhibition, verbal/physical 
aggression, poor responses to 
medications
Previous poly-
substance misuse 
(variable)
a) RIS-LAI (37.5 
mg fortnightly, NA), 
OLA (10 mg daily, 
NA) pregabalin (100 
mg daily, NA) b) ARI 
(30 mg daily, NA), 
lithium carbonate 
(800 mg daily, NA) 
c) HALO-LAI (50 mg 
monthly, NA), HALO 
(10 mg daily per os, 
NA) d) ARI-LAI (400 
mg monthly, NA)
Sweet et al. (86) Case report (USA) 1, 47, African-
American, M
None SC Bizarre behavior, delusions, 
hallucinations, agitation, 
aggressiveness
NA OLA (10 mg 
daily, NA), HALO 
(10 mg im, NA), 
LORA (2 mg, NA), 
dipgenhydramine 
(50 mg, NA)
Skryabin and 
Vinnikova (87)
Single-center analysis 
cohort study (Russia)
46, 23.2 ± 3.5 
(mean), NA, M
NA SC Delirium, tactile hallucinations, 
auditory verbal hallucinations, 
Kandinsky–Clerambault's syndrome 
delusion of influence, automatisms, 
anxiety, paranoia, delusional mood, 
agitation, delusional persecutory 
ideas, thought insertion or 
withdrawal, etc.
Cannabis, alcohol NA
Studies on synthetic cathinone-induced psychosis
Antonowicz 
et al. (88)
Case report (USA) a) 1, 27, NA, F b) 
1, 32, NA, M
None "Powdered Rush" 
containing MDPV
a) Tachycardia, diaphoresis, paranoid 
psychosis, disorganized though 
process, poor memory, insomnia 
b) Hypertension, tachycardia, 
disorganized behavior, paranoid 
psychosis, insomnia
Previous history of 
opiate dependence
a) Hospitalization, 
RIS (0.5 mg 
BID, NA) b) 
Hospitalization, 
refusal of any 
medications
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Derungs et al. 
(89)
Case report 
(Germany)
1, 31, NA, M NA Naphyrone powder 
ingestion
Blurred vision, restlessness, anxiety, 
dysphoria, hallucinations, insomnia, 
paranoia
Regular MDMA, 
alcohol and 
benzodiazepine 
abuse
NA
Penders and 
Gestring (90)
Case report (USA) 3, NA, NA, 2 M 
and 1 F
None MDPV Hyperactivity, anger, confusion, 
hallucinations, paranoia, anxiety, 
fearful, insomnia
NA Hospitalization, RIS 
(n = 2, 0.5 mg orally 
BID, NA), HALO 
(n = 1, 1 mg orally 
BID, NA)
Striebel and 
Pierre (91)
Case report (USA) 1, 22, NA, M None MDPV Anxiety, hallucinations, chest pain, 
diaphoresis, nausea, tachycardia
Regular cannabis use Hospitalization, 
supportive care, 
LOR (NA, NA)
Adebamiro and 
Perazella (92)
Case report (USA) 1, 26, NA, M NA Synthetic cathinones Diaphoresis, kidney dysfunction, 
confusion, paranoia, agitation, 
hallucinations, hypertension, 
tachycardia
NA Hospitalization
Kasick et al. (93) Case report (USA) a) 1, 38, 
Caucasian, M b) 
1, 26, Caucasian, 
M
None "Arctic Blast" and "Posh 
Aromatherapy Bath Salts" 
containing synthetic 
cathinones
a) Snakes hallucinations, 
aggressiveness, tachycardia, 
hyperthermia, agitation, alertness, 
anxiety, paranoia b) Auditory 
hallucinations, feelings of 
detachment, derealization, paranoia, 
suicidal ideation, confusion, delirium, 
tremors, hyperreflexia, myoclonus, 
amnestic effects
NA a) Hospitalization, 
LOR (13 mg IV, 
NA) and supportive 
therapy ev, 
then HALO (5 
mg IM, NA) b) 
Hospitalization, LOR 
(5 mg IV, NA), RIS 
(0.5 mg daily, NA)
Lajoie and Rich 
(94)
Case report (USA) 1, 50, NA, M None MDPV Agitation, hallucinations, psychosis, 
suicidal ideation, chest pain, skin 
lacerations, tachycardia
History of 
methamphetamine 
abuse
Hospitalization, 
LOR (NA, NA), OLA 
(NA, NA)
Thornton et al. 
(95)
Case report USA) 1, 23, NA, M Personal psychiatric 
history of psychotic 
disorder not better 
specified
MDPV Bizarre behavior, suicidality, visual, 
tactile and auditory hallucinations, 
agitation, tachycardia, hyperthermia
NA Hospitalization, LOR 
(6 mg daily, NA), 
droperidol (2.4 mg 
daily, NA)
Gunderson et al. 
(96)
Case report (USA) 1, 20, NA, M Personal psychiatric 
history of MDD
"Infinity", "TranQuility," 
"Cool Wave," "White 
Lightning" containing 
synthetic cathinones + 
diphenhydramine
Irritability, weight loss, insomnia, 
hallucinations "seeing different things, 
including people walking around his 
yard and house dressed all in white, 
having sex in his yard, chanting, 
etc."), suicidal ideation, paranoid 
psychosis, defensive homicidality
Previous cocaine, 
alcohol and opioid 
dependence in stable 
remission Previous 
cannabis and SC 
consumption
Hospitalization
Khan et al. (97) Case report (USA) 1, 19, NA, F None "Ivory Wave" containing 
synthetic cathinones
Severe agitation, aggressive behavior, 
psychosis, poisoning delusion, 
auditory and visual hallucinations, 
vernal aggressiveness, labile 
mood, tachycardia, hypertension, 
diaphoresis, mydriasis
None Hospitalization, LOR 
(NA, NA) and OLA 
(NA, NA)
(Continued)
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TABLe 2 | Continued
Reference Study design 
(country)
Sample 
features (size, 
age, ethnicity, 
sex)
Psychiatric history NPS involved Symptomatology Previous 
substance use 
history
Treatment [drug 
name, dosage, 
duration (if 
available)]
Mangewala 
et al. (98)
Case report (USA) 1, 15, NA, M None MDPV Agitation, paranoid psychosis, 
barricading himself in his home, 
aggressiveness towards health 
professionals, Capgras syndrome
Previous cannabis 
use
Hospitalization, LOR 
(0.5 mg BID, NA), 
OLA (7.5 mg daily, 
NA)
Stoica and 
Felthous (99)
Case report (USA) 1, 30, Caucasian, 
M
Personal psychiatric 
history of bipolar 
affective disorder and 
schizophrenia associated 
with a family psychiatric 
history of schizophrenia 
and bipolar disorder
Synthetic cathinones Suicidal threats and gestures, 
auditory hallucinations, euphoria, 
increased energy level, insomnia, 
paranoid delusion ("he thought his 
neighbors were at his door, watching 
for him"), homicide ideation towards 
his neighbors
Previous heroin, 
cannabinoids, 
BDZs, LSD, and 
methamphetamine 
abuse
Hospitalization, VA 
(250 mg BID, NA), 
trazodone (100 mg 
daily, NA)
Winder et al. 
(100)
Case report (USA) 1, 33, NA, M None MDPV and mephedrone Diaphoresis, hyperthermia, 
tachycardia, agitation, dysphoria, 
euphoria, hallucinations, insomnia, 
paranoia
Prior 
methamphetamine, 
opioids, alcohol, 
benzodiazepines 
abuse
Hospitalization, LOR 
(NA, NA), QUE (NA, 
NA), unspecified AD
Bertol et al. 
(101)
Case report (Italy) 1, 27, Caucasian, 
M
Personal psychiatric 
history of bipolar disorder
MDPV ev ± 3-methyl-
methcathinone ± 
pentedrone
Mydriasis, unresponsiveness, 
agitation, delirium, visual, tactile 
and auditory hallucinations, 
persistent sleeplessness, euphoria, 
micro-zoopsia
Previous alcohol 
dependence
Hospitalization, 
diazepam (NA), 
chlorpromazine 
(NA), ARI (NA)
Stevenson et al. 
(102)
Case report (UK) 1, NA, NA, M Personal psychiatric 
history of drug-induced 
psychosis
3-MeO-PCP and MDPV Vivid hallucinations, bizarre ideas, 
violence and aggressiveness, murder 
attempt
History of regular 
recreational use of 
several illicit drugs
NA
Crespi (103) Case report (USA) 1, 17, NA, F None "Flakka" (Alpha-PVP) Altered mental status, agitation, 
psychotic behaviors, cognitive 
deterioration, bizarre behavior
NA Hospitalization, LOR 
(NA, NA) and OLA 
(10 mg BID, NA)
Dolengevich-
Segal et al. (104)
Case report (Spain) 1, 25, NA, M Personal psychiatric 
history of ADHD, 
antisocial behavior and 
early substance abuse in 
adolescence
Mephedrone in the 
context of ChemSex
Delusional paranoid ideation with 
an intense emotional and behavioral 
impact, visual hallucinations involving 
human forms and cellphone lights, 
suicide ideation, psychomotor 
restlessness, feeling of being 
"controlled," suspiciousness, 
cenesthopathy (i.e., "insects crawling 
under the skin")
Cocaine, alcohol, 
ketamine, 
GHB, MDMA, 
methamphetamine
Hospitalization, 
PALI (6 mg daily, 
NA) zonisamide 
(300 mg daily, NA), 
pregabalin (75 mg 
daily, NA)
Romanek et al. 
(105)
Retrospective 
single-center study 
(Germany)
81, 17–49, NA, 
64% M
NA Synthetic cathinones 
various
10 patients manifested prolonged 
psychosis
NA NA
(Continued)
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varying from 3% to 16.3% (26). A retrospective analysis of 
cases presenting to the ED of the University Hospital of Bern, 
Switzerland, with symptoms/signs consistent with acute toxicity 
of recreational and/or NPS use identified two intoxications 
with NPS: one with methylone and one with 2C-P; 71 cases 
of psychoses even though the authors do not clearly describe 
clinical presentation related to the NPS identified (27).
Data on Synthetic Cannabinoids
A case series described some instances of SC-induced reemergence 
of florid psychotic symptomatology among five forensic patients 
who took a mixture of SC (like “K2” and JWH-018) contained 
in “Aroma” blend (28). Psychopathological patterns comprised 
the onset of psychomotor agitation, disorganized behavior, 
and ideation, delusional beliefs (grandiose and paranoid) in 
previously stable patients with a personal history of severe mental 
illness (SMI) (28). No data are provided about pharmacotherapy 
and/or specific/suggested treatment (28).
Müller et al. (29) described a 25-year-old man, with a 
previous history of recurrent psychotic episodes triggered 
by cannabis consumption and stable on monotherapy with 
amisulpride (800 mg daily), who presented to hospital with 
increased levels of anxiety, feelings of manipulation, and 
psychotic symptoms after smoking “spice” drugs on three 
different occasions (3 g each). The subject reported the 
feeling of being controlled and manipulated through a chip 
which he thought was implanted in his abdomen several 
years before together with the onset of imperative voices and 
paranoid hallucinations, symptoms he never had before (29). 
no data are provided about pharmacotherapy and/or specific/
suggested treatment (29).
Another case report described three cases of “Mojo psychosis,” 
a mixture of SC (30). No further details on psychopathological 
presentation have been reported by the authors (30).
A study evaluating urine metabolism of SC described three 
cases of new-onset psychosis following the intake of a mixture 
blend named “Tropical synergy” containing several SC (31). 
No further data are provided on psychopathological pattern 
and/or about pharmacotherapy and/or specific/suggested 
treatment (31).
Vearrier and Osterhoudt (32) described a case of an adolescent 
girl who arrived at the ED agitated, violent, and uncontrollable 
after inhaling a “K2.” She described a previous history of alcohol 
and cannabis intake. Her psychopathological pattern comprised 
the onset of visual hallucinations, anxiety, restlessness, 
tachycardia, higher blood pressure, muscle fasciculation, 
hypokalemia, and mydriasis. She was given lorazepam 2 mg 
intravenously, with a good remission (32).
Benford and Caplan (33) reported a case of a 20-year-old honor 
college student who presented to the ED with severe anxiety/
paranoia and auditory/visual hallucinations after smoking 
“Spice” drugs. Psychopathological pattern comprised the onset 
of increasing levels of anxiety, paranoia, and both auditory and 
visual hallucinations. The subject refused voluntary psychiatric 
admission. No data are provided about pharmacotherapy and/or 
specific/suggested treatment (33).
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A case series described 11 Hispanic adolescents admitted 
to the South Miami Hospital Addiction Treatment Center 
in Miami-Dade County, Florida, after smoking SC and 
developing a new-onset psychosis (34). Subjects reported using 
Spice drugs more than three times in their lifetime (8 out of 
11 subjects), while 4 out of 11 reported smoking SC multiple 
times per day. Psychopathological patterns comprised mood 
fluctuations, altered cognition and perception (i.e., visual and 
auditory), memory difficulty, euphoria, sometimes irritability 
and anxiety, and paranoid thoughts (34). In addition, 
subjects reported tachycardia, restlessness, appetite changes, 
muscle fasciculation, tremors, and weakness. No data are 
provided about pharmacotherapy and/or specific/suggested 
treatment (34).
A cohort explorative study recruiting subjects from 
a Regional Forensic and Rehabilitation service in New 
Zealand reported a SC-induced psychotic recrudescence in 
15 vulnerable individuals previously affected with SMI (35). 
The psychopathological patterns comprised the onset of 
psychomotor agitation, disorganized behavior, and ideation, 
delusions after smoking SC. All subjects reported a previous 
psychiatric history of psychotic disorder and had been 
compulsorily treated with therapeutic doses of antipsychotics 
(unspecified) and, in five cases, together with mood stabilizers 
(unspecified). No data are provided about pharmacotherapy 
and/or specific/suggested treatment following SC-induced 
psychosis (35).
Forrester et al. (36) retrospectively collected data on 
SC exposures referred to Texas Poison Centers in 2010 
by identifying new-onset psychoses following SC intake. 
Psychopathological patterns comprised the onset of 
psychomotor agitation and hallucinations. In addition, 
tachycardia, hypertension, nausea, vomiting, drowsiness, and 
multiple neurological symptoms were reported. No further 
information is provided regarding the psychopathology and 
phenomenology of SC-induced psychoses. No clear data 
are provided about specific/suggested treatment following 
SC-induced psychosis, intravenous fluids, benzodiazepines, 
oxygen, and antiemetics being reported, among the most 
commonly prescribed medications and, in around 3% of 
subjects, the use of sedatives and anticonvulsants (36).
Hurst et al. (37) described 10 cases of otherwise healthy men, 
admitted to the psychiatry ward at the San Diego Naval Medical 
Center between August and December 2010, who experienced 
a SC-induced new-onset psychosis. The psychopathological 
patterns were characterized by auditory and visual hallucinations, 
disorganized behavior and speech, suicidal ideation, alogia, 
insomnia, psychomotor agitation and/or retardation, and higher 
levels of anxiety. No clear data are provided about specific/
suggested treatment following SC-induced psychosis, use of 
antipsychotics (unspecified) being reported in 10 patients (36).
A case report of a 23-year-old high-functioning Caucasian 
Navy corpsman who developed a SC-induced psychosis was 
reported by Johnson et al. (38). The psychopathological pattern 
comprised the onset of nonsensical speech, paranoia of being 
videotaped, disorganized behavior and speech, tangential 
thoughts, delusional ideation (i.e., the feeling of own “mind 
expanded” and the ability to “comprehend infinity,” and so on) 
without perceptual distortions. The psychotic symptoms of the 
subject spontaneously resolved after abstinence from SC about 
24 h after initial presentation. No data are provided about 
psychopharmacology and/or specific treatment of SC-induced 
psychosis (38).
Data collected retrospectively by the Italian database of the 
Pavia Poison Centre reported 17 cases of SC users who exhibited 
various psychiatric and clinical patterns, including tachycardia, 
agitation/anxiety, confusion, hallucinations, mydriasis, paresthesia, 
palpitations, drowsiness, xerostomia, syncope, seizures, vertigo, 
tremor, hypertonia, coma, etc. (39). The authors reported 
symptomatic treatment and benzodiazepines for treating 
neuroexcitatory effects (39). No further details regarding 
psychopathological pattern of SC-induced psychosis were reported 
by Locatelli et al. (39).
McCain et al. (40) retrospectively described six cases of 
SC-induced psychopathological/clinical pattern referred to the 
Arkansas Poison and Drug Information Center. Psychopathological 
patterns comprised agitation, irritability, and hallucinations. 
Benzodiazepines, intravenous fluids, antiemetics, and potassium 
supplementation were prescribed, among treatments, without 
details about dosage(s) and/or treatment duration (40).
Simmons et al. (41) described three cases of young adults 
referred to an ED after “Spice” intake (JWH-018 and JWH-073) 
who exhibited anticholinergic and sympathomimetic clinical 
effects and a new-onset SC-induced psychosis. Benzodiazepines 
(intravenous lorazepam, 4 mg), antipsychotics (haloperidol, 
5 mg), supportive therapy, and observation were among the 
treatments prescribed (41).
A 17-year-old adolescent boy without significant previous 
psychiatric and medical history presented to an ED reporting 
“pounding in his chest,” constant chest pressure, and a new-
onset SC-induced psychosis after smoking a SC, called K9 (42). 
No data are provided about pharmacotherapy and/or specific/
suggested treatment (42).
Other case reports of SC-induced new-onset psychoses 
have been reported by McGuinness and Newell (43). 
Psychopathological patterns comprised aggressiveness, paranoia, 
short-term memory deficits, and increasing levels of anxiety. 
No data are provided about pharmacotherapy and/or specific/
suggested treatment (43).
Tung et al. (44) described a 36-year-old male real-estate 
agent with a previous polysubstance abuse (heroin, codeine, and 
cannabis) with a family psychiatric history of SMI (unspecified) 
and substance use disorder (SUD) who presented an episode 
of acute psychotic disorder characterized by florid persecutory 
delusion, auditory hallucinations, disorganized behavior, 
irritability, aggressiveness, and agitation. No further data are 
provided about pharmacotherapy and/or specific/suggested 
treatment (44).
Van der Veer and Friday (45) described three patients who 
presented with severe, persisting psychotic symptoms after regular 
SC use for 3–4 weeks prior to admission. Psychopathological 
patterns comprised disorganized speech and behavior, paranoia, 
bizarre delusions, suicidality, aggressiveness, poverty of thoughts, 
loosening of associations, poor attention/concentration, and 
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inappropriate affect; onset of Capgras delusions was reported 
in one case. Two out of three patients did not have a previous 
psychiatric history, while one reported a post-traumatic stress 
disorder (PTSD). All three patients required hospitalization and 
were treated with antipsychotic medications (haloperidol in two 
cases and risperidone in one case). No further data are provided 
regarding dosage(s) and/or treatment duration (45).
Bebarta et al. (46) described three cases of “Spice” use in 
military members followed by onset of psychotic symptomatology. 
Psychopathological patterns comprised the onset of paranoia, 
aggressiveness, agitation, and visual hallucinations. Regarding 
the treatment, intravenous lorazepam 2 mg was reported for 
managing agitation, with resolution of symptomatology (46).
Cohen et al. (47) reported three cases of adolescents who 
presented with a new-onset SC-induced psychosis characterized 
by catatonia, psychomotor agitation, and aggressiveness. No 
further data are provided about pharmacotherapy and/or 
specific/suggested treatment (47).
A retrospective series of exposures to SC coming from the 
US National Poison Data System between January and October 
2010 were analyzed by Hoyte et al. (48) by identifying new-onset 
psychosis induced by SC products. No further data are provided 
either regarding further specific psychopharmacological 
treatment beyond benzodiazepines or about psychopathological 
patterns of SC-induced psychosis (48).
Two adolescents who manifested a new-onset SC-induced 
psychosis have been reported by Oluwabusi et al. (49). Both 
patients reported a family psychiatric history for schizophrenia 
and/or bipolar disorder. Psychopathological pattern comprised 
disorganized behavior, paranoid delusions, insomnia, 
hyperactivity, anxiety, musical auditory hallucinations, mood 
lability, irritability, euphoria, pressure of speech, flights of ideas, 
paranoia, and grandiose delusions. Regarding treatment, one 
subject was firstly stabilized on quetiapine and then changed to 
aripiprazole (20 mg daily) after the onset of an acute dystonic 
reaction, while the other one was prescribed olanzapine (15 mg 
daily bedtime) (49).
Another case report has been described of a new-onset 
SC-induced psychosis in a 59-year-old Latino male with a history 
of PTSD and polysubstance abuse (heroin, cocaine, cannabis, 
and alcohol) (50). His psychopathological pattern comprised 
visual hallucinations and disorganized and bizarre behavior. He 
was treated with benzodiazepines, gabapentin (400 mg QID), 
hydroxyzine (25 mg TID), aripiprazole (10 mg qD), benztropine 
(1 mg BID), and bupropion (150 mg BID) (50).
An Internet-based survey reported the onset of psychotic 
symptomatology in 28% of a sample (n = 168) of SC users 
recruited from 13 different countries (51), while an Australian 
online survey (n = 316) reported paranoia (18%) and psychosis 
(4%) (52). No further data are provided about pharmacotherapy 
and/or specific/suggested treatment in both surveys (51, 52).
Berry-Cabán et al. (53) described a 20-year-old Hispanic 
male who presented to an ED due to an altered mental status 
and delirium following SC intake. Initially, the subject was 
uncommunicative, awake then non-compliant, combative, 
and aggressive; hence, clinicians applied physical restraint 
and firstly administered 2 mg/ml parental lorazepam for 
managing increasing levels of agitation. During hospitalization, 
he was additionally treated with further 4 mg of lorazepam, 
5 mg of haloperidol, and 25 mg of diphenhydramine. His 
psychopathological pattern comprised agitation, aggressiveness, 
disorganized speech and behavior, hallucinations, and paranoid 
ideation. He was discharged with a prescription of risperidone 
1 mg daily. No further data on treatment duration has been 
provided (53).
Chan et al. (54) described a 21-year-old man without a 
previous psychiatric history who presented to an ED due to the 
onset of increasing levels of psychomotor agitation and paranoid 
thoughts after consuming 0.4 g of 6-APB and smoking cannabis 
over a 2-day period. Psychopathological pattern comprised 
agitation, paranoia, the belief that others could read his mind, 
self-harm, and suicidality. He was treated with diazepam 
(4–10 mg daily) for managing agitation during hospitalization. 
No further data have been provided regarding further treatments 
to be prescribed and/or treatment duration (54).
A retrospective cohort study targeting individuals seeking 
emergency treatment after SC intake and selected from the 
database of the Freiburg Poisons Information Center between 
September 2008 and February 2011 reported a plethora of physical 
symptoms and psychotic presentation (55). Psychopathological 
patterns included visual and auditory hallucinations, confusion, 
agitation, delirium, restlessness, and psychotic symptoms. 
Supportive care, talk down strategies, intravenous fluids, 
potassium supplementation, and benzodiazepines were 
prescribed. No further data have been provided regarding 
specific psychopharmacotherapy and/or treatment duration and/
or dosage(s) (55).
A case report of an Italian male who consumed "Bonzai," a 
mixture of SC, has been presented by Papanti et al. (7). The subject 
did not have any psychiatric history and his psychopathological 
pattern was characterized by increasing levels of anxiety, 
insomnia, ideas of reference, somatic and visual hallucinations, 
autoscopy, and aggressiveness. He was initially treated with 
diazepam 5 mg intravenously and was rehydrated, and then he 
was prescribed olanzapine 5 mg daily and bromazepam 3 mg 
daily for 4 weeks (7).
Glue et al. (56) retrospectively collected data on 17 patients 
hospitalized in an acute psychiatric ward, located in New 
Zealand, following the use of a SC (“K2”) and described their 
clinical and psychopathological features. Nine out of 17 patients 
had recurrences of preexisting disorders and four presented 
with new psychotic symptoms. Psychopathological patterns 
comprised paranoia, thought disorder, disorganized behavior and 
speech, anxiety, mood lability, and intense suicidal thinking and/
or behavior. Antidepressants and antipsychotics (unspecified) 
were prescribed, without specifying treatment duration and/or 
dosage(s) (56).
Leibu et al. (57) described a case of a 36-year-old African-
American man with a previous long-lasting psychiatric history 
of schizophrenia who presented with severe and life-threatening 
catatonia after consuming SC. Catatonia was successfully treated 
with electroconvulsive therapy, while psychotic symptoms have 
been managed with 225 mg BID clozapine (57). No further data 
are available regarding treatment duration (57).
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A Turkish survey carried out on a sample of 158 patients who 
were admitted to Bakirkoy Research and Training Hospital for 
Psychiatry, Neurology and Neurosurgery, Alcohol and Drug 
Research, Treatment and Training Center (AMATEM) revealed a 
new onset of hallucinations and delusions among SC consumers 
(58). Psychopathological patterns comprised increasing levels 
of anxiety (75.6%), irritability (18.6%), insomnia (61.5%), 
hallucinations (40.4%), and delusions (16%). No data have been 
provided regarding specific psychopharmacological treatment of 
SC-induced psychosis (58).
A case series of four paranoid schizophrenic patients who 
took SC showed a worsening of psychotic symptomatology 
(59). All subjects were hospitalized and were previously 
prescribed specific medications for their psychiatric disorder 
(i.e., haloperidol decanoate, quetiapine, risperidone, diazepam, 
clozapine, lorazepam, olanzapine, clonazepam, and fluoxetine). 
Psychopathological patterns comprised cognitive deficits, 
anhedonia, dysphoria, avolition, blunted affect, incoherent 
speech, thought blocking, severe agitation, increasing levels 
of anxiety, and so on. The subjects were furtherly treated 
by increasing benzodiazepine dosages (lorazepam and/or 
diazepam) (59).
Haro et al. (60) described a 19-year-old Hispanic woman 
who developed a psychotic episode after consuming SC. Her 
psychopathological pattern comprised self-references when 
eating or walking, visual hallucinations, soliloquy, laughter forfeit, 
catatonia, depersonalization, and derealization. After 2 months 
of abstinence from SC and treatment with aripiprazole (15 mg 
daily), lorazepam, and biperiden, psychotic symptomatology 
partially resolved (60).
Meijer et al. (61) described a case of bilateral upper-extremity 
self-mutilation and new-onset SC-induced psychosis in a healthy 
26-year-old man presented to an ED, with a previous history of 
attention deficit hyperactivity disorder (ADHD), treated with 
lisdexamfetamine dimesylate. His psychopathological pattern 
comprised the onset of paranoid delusions causing him to feel 
his hands were going to harm him, then he placed them on 
the stove and attempted to burn them off to “get the devil out 
of him.” No further data have been provided regarding the 
psychopharmacological treatment following the discharge (61).
A 17-year-old male who developed catatonia and new-onset 
SC-induced psychosis was reported by Smith and Roberts (62). 
His psychopathological pattern comprised confusion, bizarre 
behavior, mutism, rigidity, excitatory catatonia, auditory and 
visual hallucinations, and disorganized thoughts. Lorazepam 
2 mg intramuscular was administered for managing agitation, 
followed by six sessions of electroconvulsive therapy and 
olanzapine. No further data have been provided regarding 
dosage(s) and/or treatment duration (62).
Durand et al. (63) described a case of new-onset SC-induced 
psychosis associated with severe rhabdomyolysis after consuming 
SC in a 23-year-old man without prior psychiatric history. His 
psychopathological pattern comprised altered mental status, 
severe agitation, acute psychosis, irritability, persecutory 
delusions, and impulsiveness. Intravenous lorazepam every 6 h 
was prescribed for managing agitation, then haloperidol 10 mg 
TID, valproic acid 500–1,000 mg, and lorazepam 2 mg TID. No 
further data on treatment duration has been provided (63).
Schwartz et al. (64) reported seven cases who presented 
simultaneously at a hospital in Georgia (USA), after smoking a 
mixture of SC contained in a blend named “Crazy Clown” during 
a party. Psychopathological patterns comprised a new onset 
of SC-induced psychosis, aggressiveness, extreme agitation, 
and increasing levels of anxiety. Regarding the treatment, two 
patients were admitted to the intensive care unit due to persistent 
hypertension and tachycardia and mental status alterations 
and were intubated. One patient presented with cardiac arrest 
and was resuscitated by paramedics and underwent successful 
balloon angioplasty; the other subjects were not treated 
due to non-compliance and/or spontaneous remission of 
symptomatology. No further data have been provided regarding 
specific pharmacological treatment (64).
Ustundag et al. (65) described a case of SC-induced mania with 
psychotic symptoms in an 18-year-old single boy who developed 
an increasing speech, spending money, a great deal of interest 
in religion and insomnia, mystic delusions, irritability, euphoria, 
mood lability, and without hallucinations after consuming SC. 
Olanzapine (from 10 to 20 mg daily), valproic acid (from 500 
to 1,500 mg daily), quetiapine (from 200 to 400 mg daily), and 
lorazepam (from 0,5 to 1 mg daily) were prescribed. No further 
data on treatment duration are available (65).
Sönmez and Köşger (66) described a 31-year-old man who 
developed a new-onset SC-induced psychosis after consuming a 
mixture of SC called "Bonsai" three times a week for more than 6 
months and was treated with olanzapine.
Rahmani et al. (67) described two cases with a strong family 
psychiatric history who developed a SC-induced psychosis 
following the intake of “Spice.” Psychopathological pattern 
comprised the onset of paranoia, bizarre and disorganized 
behavior and speech, and visual hallucinations. No further 
data have been provided regarding treatment duration and/or 
dosage(s) of clozapine prescribed in both cases (67).
An observational case series (n = 35) retrospectively collected 
laboratory analysis of patients presenting to an ED with a 
documented suspicion of SC intake and described a new onset 
of SC-induced psychosis (68). Psychopathological patterns 
comprised altered mental status (61%), hallucinations (6%), and 
seizures (40%). Five patients were ventilated and intubated. No 
further data on specific psychopharmacological treatment has 
been provided (68).
A cross-sectional study recruiting 81 male patients diagnosed 
with SC-induced psychotic disorder (n = 50) or with schizophrenia 
(n = 31) who were concurrently hospitalized described a higher 
rate of suicidal ideation, involuntary hospitalization, as well as 
similar clinical picture with schizophrenia by inducing paranoia, 
disorganized behavior, visual and auditory hallucinations, 
and suicidal thoughts, not only in vulnerable subjects but 
also in subjects without a previous history of psychosis (69). 
Furthermore, verbal learning, short-term memory and working 
memory, executive functions, abstract ability, and decision-
making and attention functions were reported to have been 
impaired among SC-induced psychotic subjects (69).
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Khan et al. (70) described two cases of SC-induced catatonic 
state associated with psychosis, psychomotor alterations, speech 
and behavior disorganization, flatted affect, alogia in a 17-year-
old male with no psychiatric history who presented to the ED 
with psychosis after a 2-week Spice binge and in a 21-year-
old male who reported a history of childhood ADHD with 
progressive isolation and negative symptoms after heavy SC 
consumption. The first case was treated with aripiprazole 7.5 mg 
daily and lorazepam (2 mg BID), then olanzapine (unspecified 
dosage) and valproic acid (up to 100 mg qHS) were added while 
aripiprazole was tapered off, while the second case was treated 
with lorazepam for managing catatonia and firstly risperidone 
(1–2 mg BID), then switched to aripiprazole (5 mg daily, titrated 
up to 25 mg daily) (70).
A retrospective observational case series of patients (n  = 
22) presenting to an ED with analytically confirmed SC 
intake were described from a pharmacological, toxicological, 
and clinical point of view by Hermanns-Clausen et al. (71). 
Psychopathological patterns comprised restlessness, agitation, 
and visual hallucinations. Treatment was mainly supportive, 
benzodiazepines (unspecified), metoprolol, and antiemetics. 
No further data have been provided regarding dosage(s) and 
treatment duration (71).
A retrospective chart study (n = 594) evaluating all patients 
who were admitted to a dual diagnosis psychiatric unit at Mount 
Sinai Beth Israel in New York City compared SC users vs. 
cannabis users by reporting more psychotic symptoms (p = .012) 
and more agitation (p < .001) among SC consumers (72). Among 
medications, more antipsychotics alone (31.4% vs. 19.6%) or a 
combination antipsychotic plus mood stabilizers/antidepressants 
(57.1% vs. 33.5%) were prescribed among SC-only users 
compared to cannabis-only users (72).
A case report described an 18-year-old antipsychotic-
naive African-American male without past psychiatric history 
admitted after presenting to the psychiatric emergency room 
with a first-time psychotic episode after a prolonged SC ingestion 
via inhalation (73). The subject was treated with intermittent 
doses of lorazepam 2 mg orally and stabilized over 1.5 weeks on 
oral risperidone (5 mg daily) (73).
An 18-year-old Hispanic male admitted to the ED after 5 days 
of acute-onset auditory hallucinations, paranoid delusions, and 
panic attacks with a previous history of cannabis abuse and more 
recently of SC, purchased from Internet blog websites, has been 
described by Samaan et al. (74). No further data about specific 
psychopharmacological treatment of SC-induced psychosis has 
been provided (74).
Ozer et al. (75) described a case of an adolescent with a 
new-onset psychosis following inhalation of a mixture of SC 
called “Bonsai.” Olanzapine (10 mg daily) was prescribed and 
the subject was followed up 3 months after discharge without a 
recurrence of psychotic symptoms (75).
A cohort study reported, among SC consumers, higher 
psychotic levels compared to cannabis users (76). No further data 
about specific psychopharmacological treatment of SC-induced 
psychosis has been provided (76).
A retrospective cohort study recruiting data from the UK 
National Poisons Information Service reported hallucinations 
and paranoia as consequences of SC intake (77). No further data 
about specific psychopharmacological treatment of SC-induced 
psychosis has been provided (77).
A case–control neuroimaging study comparing SC users vs. 
healthy controls, using magnetic resonance imaging, reported 
that chronic SC use was associated with dose-dependent 
downregulation of CB1 receptors, lower fractional anisotropy 
(FA) values in the left inferior fronto-occipital fasciculus (IFOF), 
and inferior longitudinal fasciculus (ILF) in the left temporal 
lobe which might be associated with increased risk of the 
development of psychosis (78). No further data about specific 
psychopharmacological treatment of SC-induced psychosis has 
been provided (78).
A case report described a patient who developed acute 
psychosis, aggressiveness (e.g., homicidal and violent behavior 
towards staff), and new-onset refractory status epilepticus 
necessitating emergent neurological life support and prolonged 
admission to an intensive care unit following SC consumption 
(79). The patient was treated with intravenous lorazepam, 
valproic acid, levetiracetam, and lacosamide. Following a 
3-week hospitalization in the intensive care unit, the patient 
was discharged and followed up at 1 month. No further data on 
dosage(s) and/or treatment duration are available (79).
A cohort study systematically described the clinical 
characteristics of 100 SC users in a large sample from an urban 
public hospital in New York City by reporting a high rate of acute 
psychotic symptoms, particularly among the already socially 
vulnerable and psychiatrically ill population of the sample 
(80). Most SC users (73.7%) were prescribed an antipsychotic 
medication on discharge. No further data on dosage(s) and 
treatment duration (80).
Monte et al. (81) collected data from the US ToxIC (2010–
2015) and found that among 353 SC consumers, about 40% had 
SC-induced delirium and toxic psychosis.
A qualitative study of six SC users in Hungary revealed the 
onset of paranoia and a synthetic psychosis among participants 
(82). Similarly, an online survey reported the onset of agitation, 
paranoia, and other psychotic symptomatology following SC 
intake (83). No further data are available regarding specific 
psychopharmacological treatment of SC-induced psychosis in 
both studies (82, 83).
A prospective pilot study recruiting 332 patients with cannabis 
and/or SC use evaluated the psychosis-inducing potential of 
cannabis vs. SC, reporting more severe psychotic symptoms 
among SC vs. cannabis users (84). No further data about specific 
psychopharmacological treatment of SC-induced psychosis has 
been provided (84).
A case series described four patients taking SC and presenting 
to a UK acute psychiatric unit with a SC-induced psychosis 
by reporting mixed hallucinations, persecutory delusions and 
thought disorganization, physical and verbal aggressiveness, and 
sexual disinhibition (85). All subjects recruited were treated with 
benzodiazepines and antipsychotic drugs, as shown in Table 2.
A 47-year-old African-American man presented for 
involuntary inpatient psychiatric admission after being brought 
in by police secondary to bizarre behavior/hallucinations/
agitation/delusions following SC intake (86). He was initially 
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treated with olanzapine (10 mg daily), then switched to 
haloperidol intramuscularly and lorazepam due to aggressiveness 
and increasing levels of agitation towards clinicians. The patient 
was observed and he refused any follow-up and/or medication 
after discharge (86).
A single-center cohort study evaluating hospitalized 
SC-induced psychotic patients in a Russian hospital identified 
specific clinical variants of psychoses among SC users (87). No 
further data about specific psychopharmacological treatment of 
SC-induced psychosis has been provided (87).
Data on Synthetic Cathinones
Antonowicz et al. (88) described two cases of paranoid synthetic 
psychosis in a 27-year-old female and in a 32-year-old male 
who consumed MDPV. Psychopathological patterns comprised 
the onset of paranoid ideation, disorganized thought process, 
insomnia, and agitation. The first subject was successfully treated 
with low doses of risperidone, while the second case refused any 
medications (88).
Penders and Gestring (90) described the onset of a 
hallucinatory delirium following use of MDPV in three cases 
who presented to an ED of a tertiary care hospital in the USA. 
Two cases were successfully managed with risperidone (0.5 mg 
orally BID), while the third one was treated with haloperidol 
(1 mg orally BID) (90).
Striebel and Pierre (91) described a 22-year-old man without 
any previous psychiatric history who used cannabis regularly 
to manage his Crohn's disease and who developed a new-onset 
MDPV-induced psychosis. His psychopathological pattern 
comprised the onset of hallucinations, altered perceptions, 
“seeing things move that shouldn't be moving,” feeling an 
earthquake, and agitation. He was treated with lorazepam and 
supportive care (91).
Lajoie and Rich (94) described a 50-year-old male with 
a previous history of methamphetamine dependence who 
developed a MDPV-induced psychosis characterized by self-
mutilation, suicidality, agitation, increasing levels of panic attack, 
and auditory hallucinations. He required sedation with olanzapine 
and lorazepam, for managing agitation. No further data on 
dosage(s) and treatment duration have been provided (94).
Thornton et al. (95) reported a 23-year-old man with a previous 
psychiatric history who presented to an ED after developing 
a bizarre and disorganized behavior, suicidality, visual, tactile, 
and auditory hallucinations, and agitation following the intake 
of MDPV. He was treated with 6 mg of lorazepam and 2.4 mg 
of droperidol intravenously over 90 min in order to manage the 
agitation. He was also taking aripiprazole, valproic acid, lithium, 
quetiapine, and clonazepam for his psychiatric disorder. No further 
data on treatment duration and/or dosage(s) are available (95).
Winder et al. (100) described MDPV-induced paranoid 
psychosis in a 33-year-old male veteran without a previous 
psychiatric history. He was treated with as-needed doses of 
quetiapine and lorazepam for paranoid ideation, agitation, and 
anxiety. Symptomatology resolved within 12 h after admission. 
He was then started on an antidepressant (unspecified) for 
residual symptoms of depressed mood, anhedonia, and 
hopelessness. No further data on treatment duration and/or 
specific psychopharmacological treatment for MDPV-induced 
psychosis are available (100).
Bertol et al. (101) described a case of mixed MDPV and 
benzodiazepine intoxication in a 27-year-old chronic abuser 
with a previous SUD and a psychiatric history who developed 
severe agitation, disorganized and bizarre behavior, suicidality, 
and visual, tactile, and auditory hallucinations. He was managed 
with diazepam intravenously due to agitation and then he 
started chlorpromazine due to sleeplessness and aripiprazole for 
managing psychotic symptoms. No further data on treatment 
duration and/or dosage(s) are available (101).
Mangewala et al. (98) reported a psychotic onset (i.e., 
delirium, agitation, paranoia, and hallucinations) in a 16-year-
old adolescent man without a previous personal and/or family 
psychiatric history who abused synthetic cathinones. He was 
treated with a combination of olanzapine (from 5 to 7.5 mg daily) 
and lorazepam (0.5 mg BID) (98).
Derungs et al. (89) reported a case of paranoia and 
psychosis induced by Naphyrone in a 31-year-old man. 
Psychopathological pattern comprised agitation, restlessness, 
insomnia, anxiety, and hallucinations. No further details have 
been provided regarding a specific psychopharmacological 
treatment of synthetic psychosis (89).
Two cases of severe intoxication delirium with paranoid 
psychosis and hallucinations following “bath salts” consumption 
are described by Kasick et al. (93).
Khan et al. (97) described a case of a 19-year-old female, 
without a family and/or personal psychiatric history, who 
developed a paranoid psychosis after consuming synthetic 
cathinones. She was treated with olanzapine and lorazepam. No 
further data on dosage(s) and/or treatment duration have been 
provided (97).
Adebamiro and Perazella (92) reported a case of a new-onset 
psychosis associated with renal and cardiovascular dysfunction 
following “bath salts” intoxication. The subject was treated with 
supportive care and hospitalized (92).
Gunderson et al. (96) described a case of paranoid psychosis 
induced by “bath salts” and diphenhydramine in a subject with a 
previous psychiatric history of major depressive disorder (MDD).
Stoica and Felthous (99) described a case of acute psychosis 
in a 30-year-old subject with a psychiatric diagnosis of bipolar 
affective disorder and schizophrenia following the intake of 
synthetic cathinones. Psychopathological pattern comprised 
suicidality, homicidal tendencies, euphoria, alertness, paranoid 
delusion, and increased levels of energy. The subject was 
hospitalized and started initially on valproic acid (250 mg 
orally BID) and trazodone (100 mg daily at night) for managing 
impulse dyscontrol and insomnia. No further data are available 
on treatment duration (99).
A case report described a psychotic onset, associated with 
the attempted murder of his father, in a man with a history of 
regular recreational use of a wide range of illicit drugs between 
14 and 20 years following the intake of 3-methoxyphencyclidine 
(3-MeO-PCP) and MDPV (102). The patient experienced vivid 
hallucinations (auditory, visual, and tactile), panoramic visual 
hallucinations (“full brown eyes closed visuals” and imperative 
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voices saying “kill your father”), and bizarre ideas (e.g., “using 
house as a base for super heroes”), without other symptoms of 
schizophrenia such as delusional beliefs or thoughts disorder (102).
Several case reports of alpha-PVP (aka “Flakka”)-induced 
psychosis have been described (103, 106, 107). Crespi et al. 
(103) described a 17-year-old who developed a Flakka-induced 
prolonged psychosis characterized by altered mental status, 
agitation, auditory hallucinations, disorganized behavior, and 
psychotic symptoms. She was managed with olanzapine and 
lorazepam (103). A 20-year-old male who ingested one tablet 
of Flakka developed a psychosis characterized by agitation, 
aggressiveness, hyper-religiosity, command auditory and visual 
hallucinations of serpents, suicidality, homicidal tendencies, 
and delusions. He was initially managed with 2 mg of lorazepam 
intramuscularly for agitation, then he was prescribed oral 
lorazepam 2 mg TID and aripiprazole 10 mg daily for 3 weeks, 
then titrated lorazepam 3 mg TID and aripiprazole 24 mg daily. 
After modest improvement, he was switched from lorazepam 
to clonazepam (2 mg BID) only for 3 days and then restarted 
on lorazepam, while aripiprazole was modified with quetiapine 
(800 mg daily), with marked improvement of psychotic symptoms 
and catatonia (106). Simonato et al. (107) reported a case of 
“Flakka-induced” psychosis successfully treated with bupropion.
A case of psychosis onset following the use of mephedrone in 
the context of ChemSex has been reported by Dolengevich-Segal 
et al. (104), as described in Table 2.
A cohort study reported the major complication of cathinone 
use as a prolonged psychosis, with a high proportion of cases 
among MDPV and methylone consumers (107). No further details 
have been provided regarding a specific psychopharmacological 
treatment of synthetic psychosis (105).
DISCUSSION
Overall, NPS use seems to exert stronger and more persistent and 
severe effects among subjects with SMI than in healthy subjects 
(i.e., without a previous psychiatric history), mostly due to activity 
in the dopaminergic system, implicated in managing behavior 
and thought processes and in determining psychosis, or in the 
serotonergic, noradrenergic, and/or glutamatergic systems (4, 108, 
109) (as illustrated in Table 1). NPS may exert severe dissociative 
states, confusion in previously psychotic patients, relapse or 
worsening of a preexisting psychosis, persistent worsening of 
psychotic symptoms course, or the onset of a new severe psychotic 
symptomatology among healthy subjects (110, 111). In fact, 
the emergence of a psychotic symptomatology is commonly 
associated with a plethora of neurotransmission changes, e.g., 
increased central dopamine levels, cannabinoid CB1 receptor 
activation, 5-HT2A receptor activation, decreased activity in N‐
methyl‐‐aspartate receptors, and k‐opioid receptor activation. 
NPS may interfere at these neurobiological levels and facilitate the 
imbalance of several neurotransmitters and receptors (as illustrated 
in Table 1). For this reason, NPS use may really determine severe 
psychiatric symptoms, also in individuals not previously affected 
by a mental disorder. It is still unclear how the frequency of use 
(continuous vs. discontinued), the intensity of consumption (low, 
medium, or heavy), and the dosages (low vs. high dosages) may 
or not influence the development of a specific psychopathological 
pattern. Therefore, the advent of NPS has posed further clinical 
concern as not only are their clinical, toxicological and safety 
profiles often completely unknown (1) but they may also cause 
the onset of new psychopathological entities or the reemergence 
of “forgotten” psychopathological patterns, such as HPPD (4, 5).
Furthermore, the subtle gap/bridge between a “classical” vs. 
a “synthetic” psychosis is still the subject of clinical concern, as 
it seems the psychopathological, phenomenological, and clinical 
features of these two entities remain completely undefinable and 
clear. Moreover, this “gap” may have also meaningful effects in the 
choice of the best treatment and in defining the best outcome(s) 
and prognosis.
In addition, even though generically classified as NPS, not 
all NPS possess the same pharmacological and clinical profiles; 
hence, from a psychopathological point of view, clinicians may 
observe several types of NPS-induced “synthetic psychoses,” 
depending on the substance involved. Similarly, a specific NPS 
may cause different psychopathological effects in vulnerable vs. 
non-vulnerable individuals (as shown in Table 2). With regard 
to this, the model of a substance-related exogenous psychosis 
(SREP) and its toxic subtype (aka “lysergic psychoma”) may be 
helpful in shedding light to clinicians on differentiating classical/
endogenous versus synthetic (NPS-induced) psychoses, from 
a clinical perspective. Unlike “classical/endogenous” psychosis, 
SREP is characterized by the following features: a) qualitative 
and quantitative consciousness alterations (i.e., crepuscular 
state and onyroid state); b) ego disorders (i.e., somatosensory/
allopsychic); c) sensorial–perceptual disorders (i.e., visual, 
auditory, and coenesthetic); d) egodystonia (i.e., behaviors 
not coherent with self-image); e) mood swings; f) hyper-
presentation of the time/“concrete” psychoses, i.e., alteration 
of the experienced space; g) modification of body perception; 
h) anhedonia/apathy/negative symptoms; and i) dyscontrol 
impulsivity and self-/hetero-aggressiveness (112) (as shown in 
Table 3). “Lysergic psychoma” is a phenomenological construct 
characterized by the perception of an “extraneous/foreign” 
body in one’s own mind, in which the residual critical ego takes 
position against the intoxicated part of one’s own self (113). It is 
a syndrome characterized by a clear egodystonic experience in 
TABLe 3 | Classical psychosis vs. synthetic psychosis: psychopathological and 
phenomenological profile.
endogenous psychosis (classical 
psychosis)
exogenous psychosis (synthetic 
psychosis)
Lucid consciousness Crepuscular consciousness
Thought disorders Paraphrenia
Loss of contact with reality due to an 
ontological insecurity of the self
Loss of contact with reality due to an 
instability of the object ("floating world")
Primary, metaphysic, systematic 
delusion
Secondary, common, episodic delusion
Hallucinations Pseudo-hallucinations
Transcendental ego Empiric ego
Poor/absent insight, passivity Present insight, activity
Bizarre and inexplicable behaviors Aggressiveness and impulse dyscontrol
Apathy, anedonia, flattened affectivity Overexcited, excessive affectivity
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which a subject clearly feels and observes this “foreign entity” 
as an unusual experience, out of own control, accompanied by 
hallucinations (mainly visual and kinaesthetic) and delusional 
perceptions (and thoughts) which are completely resisted by the 
subject who tries to stem them (114). This psychotic experience 
is often described as self-limiting, intense, and brief and appears 
to spontaneously resolve after substance discontinuation, as also 
observed in several studies examined here (see Table 2). However, 
chronic, persistent NPS use, mainly at high dosages, may cause a 
complex, persistent, and long-lasting psychopathological pattern, 
defined as “synthetic psychosis,” a paraphrenic syndrome due 
to a NPS-induced mental automatism which causes a psychotic 
trajectory (114). Furthermore, the pharmacodynamics and 
pharmacological profile of each NPS seem to be responsible for 
the psychopathological and clinical manifestation of each NPS-
induced synthetic psychosis (as shown in Tables 1, 2, and 4) (1, 
19, 115–117). Although there is still a need to clearly discriminate 
and characterize specific psychopathological and pathognomonic 
patterns depending on the specific NPS classes involved, as 
previously stated and shown in Table 2, an attempt had been made 
here to provide a critical summary of studies in order to describe 
some NPS-induced psychopathological clusters (Table 4).
Overall, after an acute or repeated consumption of SC, 
neurological toxidromes have been described, such as mental status 
changes, panic attacks, agitation, aggressiveness, memory distortions, 
depersonalization, dissociation, catatonia, recurrent psychotic 
episodes (e.g., delusional thoughts and paranoia), and auditory and/
or visual hallucinations (1, 7, 96, 116–121). Psychosis developing in 
the context of a SC intake and/or intoxication is often described as 
endoformic (e.g., verbal hallucinations, kinesthetic automatisms, 
and delusion of grandeur or influence can be present), long-lasting 
(from 10–14 days to 4–6 weeks), and gradually self-resolve with the 
persistence of asthenic-depressive symptomatology and cognitive 
deterioration for more than 4–8 weeks (7, 38, 44, 87). However, 
several findings documented here show that SC-induced psychoses 
may persist even in those subjects without a previous history of 
mental illness and may induce the development of a schizophrenia-
like symptomatology, named “Spiceophrenia” (7, 25, 111, 122–125). 
In addition, there is evidence of a worsening/recrudescence of a 
mental health disorder (i.e., mainly an affective and/or a psychotic 
disorder) in those subjects with a preexisting mental condition 
(29, 34, 35, 50, 56–59, 61, 67, 69, 80, 84, 85, 111, 122). Some studies 
reported that SC may influence psychiatric course and prognosis, 
depending on the first age of SC exposure, psychiatric vulnerability/
predisposition, a history of a childhood trauma or other traumatic 
experiences, and specific genetic factors (67, 69, 124). Furthermore, 
SC have been supposed to determine a more severe psychosis, 
accompanied with agitation and significant sympathomimetic 
effects, compared to “classical” cannabis as SC are more potent 
full receptor agonists at cannabinoid receptors and do not contain 
cannabidiol, which possesses anxiolytic and antipsychotic properties 
(1, 7, 70, 126). Despite the evidence presented here, some authors 
maintain that it is difficult to clearly prove a causal linkage between 
SC intake and the onset of an ex novo psychosis in psychosis-
prone/vulnerable subjects and/or the exacerbation of a prodromal 
psychotic syndrome/appearance of basic symptoms (127). From a 
therapeutic perspective, benzodiazepines are useful for managing 
TABLe 4 | Clinical variants of NPS-induced psychosis.
Synthetic psychosis with 
predominant delirium symptoms 
induced by NPS mainly acting on 
GABA, Ach, DA, SER, NA, and 
GLU pathways
• Delirium
• Tactile and auditory verbal 
hallucinations
• Kandisnky–Clerambault's syndrome 
(delusion of influence, automatism)
Synthetic psychosis with 
predominant dissociative reactions 
induced by NPS mainly acting on 
GLU pathways
• Dissociation, derealization
• Somatopsychic depersonalization
• Illusions, perception distortions
• Bodily and kinesthetic hallucinations
• "Near-death" experiences
• Demonic possession experiences
• Affective blunting, anhedonia, 
anesthesia
• Ekbom syndrome (delusions of 
infestation, delusional parasitosis)
• Capgras syndrome (delusional belief 
that someone known has been 
replaced by an imposter, delusional 
misidentification syndrome)
• Cotard syndrome (delusional belief to 
be already dead, to not exist, to be 
putrefied, to have lost own blood or 
internal organs)
Synthetic psychosis with 
predominant paranoia and 
auditory hallucinations induced 
by NPS mainly acting on DA 
pathways
• Paranoia thought
• Auditory hallucinations
• Delusions of reference, persecution, 
grandeur, and jealousy
• Hypomanic states
• Aggressiveness and irritability
• Dysphoria, anxiety, and panic
Synthetic psychosis with 
predominant hallucinatory 
symptoms induced by NPS mainly 
acting on SER pathways
• Anxiety, irrational fear, and psychic 
hyperesthesia
• Acute verbal hallucinosis ± sensual 
delusion
• Visual hallucinations with vivid colors 
associated with intense emotional 
experiences (either positive or 
negative)
• (Eventually kinesthetic and/or tactile 
hallucinations)
• Auditory, olfactory, and gustatory 
hallucinations uncommon
• (Eventually paranoid delusions, with 
religious content)
• (Eventually hypomanic state, suicidal 
thoughts, and depression)
Synthetic psychosis with 
predominant affective-delusional 
symptoms induced by NPS mainly 
acting on SER and DA pathways
• Sensation of fear
• Delusional ideas of interpretation and 
reference
• Persecutory, philosophical, and 
esoteric delusion
• In some cases, manioform statements
Synthetic psychosis with 
predominant mental automatism 
induced by NPS mainly acting on 
mixed pathways
• Emotional tension
• Severe anxiety and confusion
• Delusional mood, agitation, and 
delusional persecutory ideas
• Mental, motor, and senestopathic 
automatisms
• Thought broadcasting, thought 
insertion, or withdrawal
• Speech automatism
• Kandinsky–Clerambault's syndrome 
with verbal hallucinations, delusion of 
influence and persecutory delusion, as 
well as automatism
GABA, gamma-aminobutyric acid; Ach, acetylcholine/cholinergic; DA, dopaminergic; 
SER, serotoninergic; Glu, glutammatergic; NA, noradrenergic.
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anxiety, agitation, and seizure risk, together with a supportive/
symptomatic therapy (1, 7, 30, 32, 36, 39, 41, 46, 48, 59–61, 71, 79, 
81). Olanzapine, clozapine, quetiapine, and aripiprazole represent the 
main prescribed antipsychotic treatments in SC-induced psychoses 
(1, 7, 37, 50, 57, 60, 62, 65–67, 70, 75, 85, 86), while haloperidol, 
risperidone, and paliperidone have been prescribed/used in isolated 
cases (45, 53, 63, 73, 85).
In contrast, published findings reported that synthetic cathinones 
may cause variable effects in patients with SMI, such as acute 
psychosis, agitation, violent behavior, confusion, disorientation, 
insomnia, suicidality, mood lability, and instability in patients 
affected with bipolar disorder and/or substance poly abuse, while 
tangential thought process, disorganized speech and behavior, 
paranoid delusions, and auditory and visual hallucinations are 
demonstrated in patients affected with schizophrenia, associated 
with amnesia surrounding their psychotic breaks (88, 90, 91, 93, 94, 
96, 100–102, 104, 106, 128). Treatment should be single-minded on 
managing agitation and psychosis and in supporting renal perfusion. 
Sedation may be required if the patient is markedly agitated and 
at risk of self-harm or harm other patients or health professionals 
(1, 92, 95, 97, 98, 103, 104). In particular, benzodiazepines should 
be preferred to manage physical violence, to decrease tachycardia 
and blood hypertension, to prevent seizures, and to reduce 
muscle hyperactivity, rhabdomyolysis, and renal failure (1). Use 
of antipsychotics alone should be considered as second-line 
strategy for managing agitation due to the higher risk in lowering 
seizure threshold and the higher risk in contributing to the acute 
toxicity of synthetic cathinones (1, 88, 97, 98, 106). Alternatively, 
anticonvulsants/mood stabilizers have been suggested (99).
The present review has several limitations which may restrict 
the generalizability of the findings presented here, e.g., most studies 
considered here have mainly focused on synthetic cannabinoids 
which represent the main representative NPS group, but do not 
necessarily represent all NPS-induced synthetic psychoses. In 
addition, most studies are represented by case reports, which, 
on the one hand, may represent a good tool/vehicle to provide 
more detailed psychopathological and clinical features on NPS 
consumption and NPS-induced psychosis, but it may not be greatly 
generalizable to a more representative clinical sample. Most studies 
do not report if NPS intake is acute or chronic and single or repeated, 
or do not clearly specify NPS dosage, route of administration, 
comorbid use of other substances, and so on. Furthermore, the 
present overview does not possess the scientific robustness of a 
systematic literature review as most studies are poorly comparable 
with heterogeneous outcomes and measures. Finally, from a 
therapeutic point of view, not all studies here considered provide 
data on therapeutic management and/or strategies. Moreover, those 
studies providing  therapeutic management do not always report 
dosage(s) and/or treatment duration.
CONCLUSION
The constantly and rapidly developing NPS drug scenario 
represents a challenge for public health, especially so for the field of 
addiction and mental health. Indeed, NPS consumption is usually 
associated with an imbalance of a plethora of neurotransmitter 
pathways and brain receptors, and, hence, correlated to a 
huge repertory of psychopathological trajectories. Vulnerable 
individuals (e.g., children, adolescents, and subjects affected with 
a psychiatric disorder) may be more prone to develop and/or 
worsen a psychopathological condition, particularly a psychosis 
which may have peculiar features, from a psychopathological and 
phenomenological point of view. Due to a great range of medical 
and psychopathological disturbances associated with NPS intake, 
it is detrimental for mental health professionals not to be ignorant 
about the effects, safety, and toxicity profile of NPS so far known, 
especially the most widespread ones discussed here, e.g., SC and 
synthetic cathinones. Indeed, further researches should better 
investigate their clinical and pharmacological knowledge so 
that better personalized management and treatment strategies/
guidelines can be written and disseminated.
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